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Rett Syndrome 
 
Rett syndrome (RTT; MIM 312750) is named after Andreas Rett, the pediatric neurologist in 
Vienna who first recognized the characteristic features of the syndrome in 1954. Although his 
observation was published in the German medical literature in 1966 [1], it remained largely 
unnoticed until 1983 when Bengt Hagberg from Sweden revealed this unique syndrome to the 
international medical world [2].  
In the late 1990s, researchers from Huda Zoghbi’s laboratory suggested that the MECP2 gene, 
located on the X chromosome, was a good candidate gene for RTT and, accordingly, 
identified mutations in this gene in a number of patients with Rett syndrome [3]. RTT was 
thus the first neurodevelopmental disorder related to epigenetics. Later, the CDKL5 and 
FOXG1 genes have been associated with variant forms of Rett syndrome. 
A major challenge for understanding neurodevelopmental disorders, including Rett syndrome, 
is to advance the findings from gene discovery to an exposition of the neurobiological 
mechanisms that underlie these disorders and subsequently translate this knowledge into 
mechanism-based therapeutics. 
 
 
Clinical features of Rett syndrome 
 
Rett syndrome is a neurodevelopmental condition that affects approximately 1 in 10,000 
females, which makes it the most common cause of severe female mental retardation. RTT is 
characterized by an apparently normal period of development lasting for 6-18 months, after 
which the loss of spoken language can be observed together with acquired microcephaly, 
intellectual disability, emergence of autistic features, loss of purposeful manipulation skills 
that are replaced by stereotyped hand movements, other motor abnormalities including 
abnormal muscle tone, ataxia and apraxia. RTT is considered as one of the most common 
causes of complex disability in girls as reviewed in Chahrour et al. 2007 [4]. 
For the diagnosis of classical Rett syndrome, which is based exclusively on a set of clinical 
criteria derived from expert consensus [5], the affected individuals must have had a period of 
relatively normal development after birth, followed by regression of skills as described below. 
Moreover, classic RTT has a characteristic disease progression, which has been subdivided 
into four distinct clinical stages. 
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The stagnation stage occurs between 6 months and 1.5 years of age after a period of normal 
development [2]. Sudden changes in interactive behavior of the girls can be noticed but since 
the overall developmental pattern of the child is still grossly normal, the behavioral 
declination is not always significant enough to warrant the concern of the physicians. In the 
period of active regression, occurring at 1 to 4 years of age, [2] acquired abilities, such as 
voluntary hand use and language, are completely or partially lost. In addition, some affected 
individuals show autistic traits and become socially withdrawn, disliking physical contact, 
avoiding eye gaze, and being indifferent to visual and aural stimulation. Without the 
development of more distinctive manifestations of RTT, such as the repetitive hand 
stereotypies, the diagnosis of autism may be entertained at this stage. In the third pseudo-
stationary phase, the loss of skills stops and the typical repetitive hand stereotypies, which 
represent the hallmark of the disorder, become prominent. The hand stereotypies are 
classically described as hand wringing and washing but also hand tapping/clapping or 
clasping may be manifested. The visual contact somehow returns and the child may look 
more alert and joyful with typical eye-pointing behavior to express needs and wishes. Gait 
impairment, such as dyspraxic and ataxic gait, is typically noted at this time. In this stage that 
can last for decades, the girls and women might still be able to learn new things, situations, 
and persons. Finally, in the late motor deterioration phase, a deterioration of the skeleton-
muscular apparatus is observed and RTT patients often become wheelchair dependent. Hand 
stereotypies become less intense and simpler with age. Lack of motor activity finally leads to 
a state of frozen rigidity. However, some patients never lose the ability to walk and remain in 
stage 3 throughout their lives. 
 
Besides the above described clinical features, RTT patients may suffer from growth failure, 
acquired microcephaly, gastrointestinal problems, seizures and nonepileptic spells, breathing 
and cardiac abnormalities, autistic features, and other behavioral problems.  
An impairment of the autonomic nervous system in RTT is suggested by an increased 
incidence of long Q-T intervals (measure of the time between the start of the Q wave and the 
end of the T wave in the heart's electrical cycle) during electrocardiographic recordings 
contributing to the higher incidence of sudden unexpected death in RTT patients. Even with 
the high risk of sudden death because of respiratory and cardiac dysfunctions, patients may 
survive till the 6th or 7th decade of life with limited mobility. 
Along with symptoms described above, epilepsy is very common in Rett syndrome with a 
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frequency ranging from approximately 50-90% [6,7]. The onset of epilepsy generally 
correlates with clinical stages 2-3, meaning that the seizures appear between 2-5 years of age, 
with a very small percentage occurring after the age of 10 years [8,9,10]. The severity of 
epilepsy often tends to decline after adolescence, with decreased seizure frequency and 
overall less secondary generalized seizures even in those patients who were previously 
considered quite intractable [6,10].  
 
The first group of proteins that were discovered with the potential of binding to methylated 
DNA were the methyl-CpG binding domain (MBD) proteins. The mammalian MBD family 
consists of 5 nuclear proteins, MBD 1–4 and Methyl-CpG binding protein 2 (MeCP2) [11].  
MECP2 is an X-linked gene, which was discovered as the prototype member of the DNA 
methyl binding proteins [12].  
The MECP2 gene is ubiquitously expressed in human and mouse tissues but is particularly 
abundant in the central nervous system, suggesting an important role of the protein in this 
organ. Accordingly, in 1999, mutations in the MECP2 gene were unexpectedly identified in 
patients with Rett syndrome and surprisingly the gene turned out to be the epigenetic factor; 
in the following years mutations in MECP2 have been found to account for more than 95% of 
patients with classical Rett syndrome [3,13]. 
 
 
Structure and function of MECP2 
 
The MECP2 gene maps between L1CAM and the RCP/GCP loci in Xq28 and is subject to X 
Chromosome Inactivation (XCI) in females [14,15]. The genomic locus of MECP2 spans 
approximately 76 kb and consists of four exons encoding two different isoforms (MeCP2E1 
and MeCP2E2) that are generated by alternative splicing of exon 2, as depicted in figure 1. 
Alternative 3’-UTR usage leads to a short 1.8 kb and a long 10 kb transcript that includes a 
highly conserved 8.5 kb long 3’-UTR, with a third additional low abundance transcript of 
approximately 5–7 kb [14].  
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Figure 1: The MECP2 gene and protein isoforms. Schematic illustration of the MECP2 gene 
structure (middle part) and the different domains of the two protein isoforms, MeCP2E1 and 
MeCP2E2 (upper and lower bars, respectively). Adapted from Zachariah et al. (2012) [16]. 
 
 
Along with the methyl-CpG-binding domain (MBD), through which MeCP2 binds 
methylated DNA, the protein also contains a nuclear localization signal (NLS), a 
transcriptional repression domain (TRD), and a C-terminal domain (CTD). Whereas the NLS 
directs the protein to the nucleus, the TRD generates a physical association with 
transcriptional co-repressors such as Sin3a, which recruits the histone deacetylases HDAC1 
and HDAC2 to methylated DNA resulting in a compact chromatin structure that represses 
local gene expression [17,18,19] as shown in figure 2. Recently, Baker and colleagues 
identified an AT-hook domain within the TRD of MeCP2 that plays an important role in 
chromatin organization. AT-hooks are regions of proteins that bind to AT-rich DNA and, 
accordingly, MeCP2 requires an A/T rich motif adjacent to the methylated CpG-dinucleotides 
for efficient binding [20]. The molecular function of the C-terminal domain is not entirely 
defined yet but it is supposed to be critically important for the proper functioning of the 
protein, facilitating DNA binding and protein-protein interactions [21,22].  
Of the two isoforms, MeCP2E1 is 10 times more abundant than MeCP2E2 in brain. The two 
isoforms differ only in their N-terminal sequences, thus sharing the main functional domains, 
MBD and TRD, and it seems likely that their functional properties overlap considerably. A 
number of point mutations have been identified that are unique to the MeCP2E1, indicating 
that MeCP2E1-specific mutations are sufficient to cause RTT. 
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Figure 2: The function of MeCP2 in gene silencing and chromatin compaction. As a 
transcriptional repressor, MeCP2, when bound to methylated DNA, recruits Sin3A, HDACs 
and some chromatin remodeling proteins to silence target gene transcription. Adapted from 
Xin Xu and Lucas Pozzo-Miller (2013) [23]. 
 
While more than 90% of RTT cases are caused by sporadic mutations in MECP2, eight sites 
are the most common ones and account for more than 65% of all RTT causing mutations. The 
deamination of methylated cytosines generating C>T transitions are responsible for these so-
called hotspot mutations that are depicted in figure 3. Although mutations are distributed 
throughout the gene, missense mutations tend to cluster in the MBD while, large multi-
nucleotide deletions occur in the C-terminal domain (CTD) and the most nonsense mutations 
are distal to the MBD [24]. 
 
      
 
 
Figure 3: MeCP2 hotspot mutations. Adapted from the MeCP2 mutation database 
(http://www.mecp2.org.uk/). 
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MeCP2 functions 
 
Based on a large body of evidence, MeCP2 was depicted as a transcriptional repressor and 
initially RTT was hypothesized to be caused by the deregulation of genes whose dysfunction 
was sufficient to cause the observed phenotypes. Transcription profiling experiments, 
however, failed to reveal gross changes in gene expression and only few genes such as Bdnf 
have been found consistently deregulated in the absence of MeCP2. Moreover, genome wide 
analysis of gene expression in MeCP2 mutant mice showed that MeCP2, contrary to 
expectation, could activate the expression of many genes directly or indirectly [25]. In support 
of this idea, a biochemical interaction between MeCP2 and the transcriptional activator CREB 
was reported [25]. In addition, MeCP2 has been proposed to regulate RNA splicing through 
its interaction with the splicing factor, YB1, and moreover, protein synthesis is reduced due to 
reduced mTOR activity. It is thus clear that further analyses are required to clarify whether 
MeCP2 is simply a methyl-DNA binding protein involved primarily in transcriptional 
repression or a multi-functional protein with global or local effects on chromatin. For 
instance, recent work demonstrates that MeCP2 in neurons, where it is particularly abundant, 
binds broadly throughout the genome, suggesting that it might function more as a global 
regulator of transcription and chromatin remodeling rather than as a sequence-specific 
transcription factor [26,27]. The current state of our knowledge therefore suggests that RTT 
might be caused by the misregulation of both transcription and other MeCP2 dependent 
processes.  
 
 
Expression pattern and neuronal functions 
 
Though MeCP2 protein expression is found through out the body, its expression is highly 
abundant in the central nervous system. The onset of Mecp2 expression occurs in a defined 
pattern during perinatal development, where it becomes apparent in the most ontogenetically 
ancient part of the brain, such as the brainstem and thalamic regions, where after it gets 
expressed in progressively more rostral structures during development [28,29,30]. The 
transcript levels are high during embryogenesis with a post-natal decrease, but increase again 
towards adulthood. On the other hand, the protein levels are low during embryogenesis and 
increase post-natally upon neuronal maturation [29].  
The loss of MeCP2 does not affect overall brain structure but neurons are smaller and more 
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densely packed resulting in a reduced brain volume. Moreover, decreased axonal and 
dendritic arborization and dendritic spine density are observed in hippocampal pyramidal 
neurons from Mecp2-null mice, demonstrating that the protein plays a significant role in 
regulating neuronal morphology. The levels of microtubule-associated protein 2 (MAP2) 
were also found reduced upon loss and gain of MeCP2 expression [31,32,33,34,35] in 
accordance with the involvement of MeCP2 in shaping dendritic morphology. 
The imbalanced level of MeCP2 also affects synaptic connectivity since its loss tends to 
decrease the excitatory synapse number [32,35]. Accordingly, loss of MeCP2 causes reduced 
excitatory input while the inhibitory input was enhanced indicating that the homeostatic 
balance between excitation and inhibition depends on MeCP2 [36]. 
The change in MeCP2 expression also affects LTP (long term potentiation) as evidenced by 
the fact that the loss of MeCP2 produces significant deficits in hippocampal LTP [37,38], 
while enhanced synaptic plasticity can be observed in mice with increased MeCP2 protein 
levels. This suggests that MePC2 dysfunctions might cause deficits in learning and memory 
that are actually a hallmark of MECP2 related disorders. 
Despite the low abundance of MeCP2 in glial cells, recent evidence suggests that the methyl-
binding protein may also play an important role in astrocytes and microglia [36,39,40,41]. An 
in vitro co-culture system showed that the microglia or astrocytes lacking MeCP2 inhibit 
dendritic arborization of wild-type neurons by producing a toxic factor, later proposed to be 
glutamate. In vitro evidence also confirmed that loss of MeCP2 within astrocytes leads to a 
gap junction dependent failure of affected astrocytes to properly support dendritic 
development as well. 
 
 
Phosphorylation status of MeCP2 and its influence on pathogenicity of RTT 
 
The post-translational modification (PTM), such as phosphorylation, has emerged as a 
potential mechanism to provide localized functional specificity to the widely distributed 
MeCP2. In the last years, MeCP2 has been found phosphorylated on a number of residues in 
neuronal cultures and in brain [42]; however, so far, the functional role and the upstream 
signaling of only few sites have been studied. Importantly, the phosphorylation of these sites 
is differentially induced by neuronal activity, brain-derived neurotrophic factor, or agents that 
elevate the intracellular level of 3′, 5′-cyclic AMP (cAMP), indicating that MeCP2 may 
function as an epigenetic regulator of gene expression that integrates diverse signals from the 
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environment.  
In neuronal cultures, the phosphorylation of S421, which is induced by neuronal activity, was 
found to cause the release of MeCP2 from the Bdnf promoter, suggesting a mechanism 
involved in the activity dependent induction of this gene [43]. However, genome wide in vivo 
studies showed that upon S421 phosphorylation, MeCP2 remains associated with the genome 
[27]. A further understanding of how this PTM regulates gene expression is thus still awaiting 
but its role for neuronal functions is evident since dendritic growth and spine maturation are 
dependent on the activity dependent S421 phosphorylation of MeCP2 [43,27]. Moreover, 
knock-in mice carrying a phosphor-defective mutation (S421A) developed by Cohen and 
colleagues demonstrated that neuronal activity-dependent phosphorylation of S421 is 
necessary for animals to process novel experience and respond appropriately to previously 
encountered objects or animals. Whereas S421 phosphorylation is induced by neuronal 
activity, S80 and S399 are phosphorylated in resting neurons and get dephosphorylated with 
neuronal activity [42] reinforcing the idea that MeCP2 PTMs are highly dynamic. Lately, 
activity dependent phosphorylation of T308, was found to abolish the interaction of MeCP2 
with the co-repressor NCoR and suppresses the repressive action of MeCP2 on transcription 
[44]. Interestingly, T308 phosphorylation is impaired by the RTT causing mutation R306C 
implicating that RTT in humans might be caused by disruption of important phosphorylation 
events of MeCP2. None of the phospho-defective mice models generated either by Cohen et 
al. (S421A), Tao et al. (S80A and S424A/S421A), or Ebert el al. (T308A) fully recapitulates 
the phenotypes that are observed with total MeCP2 disruption or overexpression, indicating 
the complexities in understanding the relevance of these modifications to RTT. Conclusively, 
these observations indicate that phosphorylation of MeCP2 determines its functional activity 
and that disruption of any of these phosphorylation events or its interacting partners may lead 
to neurological abnormalities in RTT. Accordingly, CDKL5, which is associated with the 
Hanefeld variant of Rett syndrome, has been proposed to act upstream MeCP2 in a common 
molecular pathway even if in vivo evidence for the capacity of CDKL5 to phosphorylate 
MeCP2 is still missing [45]. 
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The mouse models: an insight into the RTT pathogenesis 
 
To understand the molecular and cellular bases of RTT pathophysiology as well as to improve 
the basic knowledge of the role of MeCP2 for brain development and function, several mouse 
models have been generated that recapitulate a broad spectrum of RTT phenotypes. 
The Jaenisch model was generated through cre-lox recombination causing the deletion of 
exon 3 of the Mecp2 gene [46]. Male mice show normal development until 5 weeks of age 
when they start developing nervousness, body trembling, piloerection, and occasional 
breathing abnormalities. They typically experience weight loss at the age of 8 weeks and most 
of them die by the age of 10 weeks. They normally have smaller cortical neurons packed at a 
higher density and show reduced dendritic complexity in pyramidal neurons in the cortex [47] 
as well as in the hippocampal CA3 region and granule cells of the dentate gyrus [39]. The 
Bird model was obtained by deletion of exon 3 and exon 4 of Mecp2 in embryonic stem cells 
to produce a complete null in terms of the production of MeCP2 protein [48].  Hemizygous 
males start developing symptoms such as stiff uncoordinated gait, hindlimb clasping, irregular 
breathing, and uneven teeth wear only after 10 weeks. Furthermore, they start showing weight 
loss and die at around 12-16 weeks. Conversely, heterozygous females survive longer and are 
fertile. The symptoms such as inertia and hindlimb clasping start at around 3 months and later 
on breathing abnormalities and decreased mobility occur. The MeCP2308/y model was 
developed by insertion of a stop codon at amino acid 308 resulting in the expression of a 
truncated protein retaining the MBD, TRD and NLS [29]. The mice show comparatively 
milder phenotypes and survive much longer than MeCP2 null models. MeCP2308/y mice have 
impairments in hippocampal-dependent spatial memory as well as social memory.  
Additionally, Collins and colleagues developed a mouse model (Mecp2Tg1) expressing MeCP2 
at approximately 2 fold levels [49]. At the same time Luikenhuis et al. developed another 
mouse line overexpressing a Tau-MeCP2 fusion protein selectively in post-mitotic neurons 
from the Tau locus in homozygous Tau knockout mice [50]. Both transgenic models 
overexpressing MeCP2 show neurological phenotypes that are largely overlapping. The 
Mecp2Tg1 mice appear clinically normal until 10–12 weeks of age when they start exhibiting 
symptoms such as enhanced motor and contextual learning and enhanced synaptic plasticity 
in the hippocampus. However, later on, these mice develop seizures and become hypoactive 
and approximately 30% die by the age of 1 year [49]. The phenotype associated with 
increased MeCP2 levels implies that MECP2 is a dosage sensitive gene and that slight 
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perturbations in its levels are deleterious for brain functioning in mice. Accordingly, in 
humans the MECP2 duplication syndrome has in the last years been recognized as a distinct 
clinical phenotype in males [51].  
Since the viability of neurons is not affected by MeCP2 mutations and, therefore, rather than 
being a neurodegenerative disorder, RTT is considered a neurodevelopmental disorder. This 
led Guy and colleagues to test whether re-expression of Mecp2 in symptomatic mice lacking 
Mecp2 might be sufficient to rescue the RTT-like symptoms. Intriguingly, several features of 
the disease such as general health condition, LTP defects, and viability were restored [52] 
raising the possibility of a beneficial effect of gene therapy to increase MeCP2 levels in RTT 
individuals. Two other studies demonstrated that restoring Mecp2 in postmitotic neurons 
rescues the RTT-like phenotypes observed in Mecp2-deficient mice [53,50]. Even if these 
studies have provided evidence that RTT is a reversible condition, at least in mice, it is 
important to recall that neuronal functions are highly sensitive to MeCP2 levels and a gene 
therapy approach in humans must be well controlled to express MeCP2 at physiological 
levels.  
To understand whether the loss of MeCP2 in fully mature mice generate the same symptoms 
as the loss of the protein in early post-natal life, McGraw and colleagues developed an adult 
onset model of RTT by crossing mice harboring a floxed MeCP2 allele with mice carrying a 
tamoxifen-inducible CreER allele [54]. These adult knockout (AKO) mice displayed hypo-
activity, abnormal gait and hind-limb clasping after tamoxifen administration and, later on, 
the AKO mice developed motor abnormalities and impaired nesting ability as well as 
impairment in learning and memory and finally they die. These studies suggest that the 
MeCP2 functions must be continuously maintained throughout the life for proper functioning 
of the brain [54]. 
It has already been discussed in previous section that MeCP2 plays an important role in glia. 
Microglia, the brain-resident macrophages, are of hematopoietic origin and have received 
increasing attention in the pathophysiology of several neurodegenerative and neuropsychiatric 
diseases. Derecki and colleagues analyzed the role of the microglia in RTT by transplantating 
wild type bone marrow into irradiation conditioned Mecp2-null mice resulting in the 
engraftment of brain parenchyma by bone marrow derived myeloid cells of microglial 
phenotype. Interestingly, the transplantation of wild-type MeCP2-expressing microglia 
attenuates numerous facets of disease pathology in Mecp2-null male and heterozygous female 
mice. Indeed, the targeted expression of MeCP2 in myeloid cells in an otherwise Mecp2-null 
background increased the lifespan, normalized the breathing patterns and improved locomotor 
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activity, restoring the normal body weight whereas neurological symptoms remained 
unaltered [55]. This effect was found to depend on the phagocytic capacity of the microglia.  
Based on these results it has been proposed that apoptotic debris accumulates over time in the 
Mecp2-null brain, contributing to neuronal malfunction and accelerating disease progression. 
Therefore, these observations suggest the importance of microglial phagocytic activity in Rett 
syndrome and finally it can be speculated that bone marrow transplantation might offer a 
feasible therapeutic approach for this devastating disorder. 
 
 
Atypical forms of RTT 
 
A variety of specifically defined variant forms of RTT have been recognized that have distinct 
clinical features. Some of these forms have been recognized in only a small number of cases, 
making it difficult to make any clear statement concerning the defining clinical features. 
However, multiple cases have been described for three distinct variant forms of RTT, 
including the preserved speech variant [56], the congenital variant [57], and the early-onset 
seizure variant [58]. In contrast to the preserved speech variant that is the most frequent one 
and has well-defined clinical features, mutations in MECP2 have only rarely been identified 
in the congenital and the early seizure variants [59,60,61]. A varied range of mutations has 
been found in different loci associated with these variant forms such as mutations in CDKL5 
in the early seizure variant [62] and mutations in FOXG1 in patients with the congenital 
variant [63].  
 
 
Early-onset seizure variant (Hanefeld variant) of Rett syndrome 
 
The apparent lack of MECP2 mutations in a small proportion of clinically well-defined Rett 
syndrome cases suggested the existence of at least one other RTT locus. In 2005 genetic 
analyses [64,65,66] revealed mutations in the gene encoding cyclin dependent kinase-like 5 
(CDKL5) in patients who had been diagnosed with atypical Rett syndrome but without 
mutations in MECP2, supporting the existence of genetic heterogeneity in RTT. 
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History 
 
In 1985, Folker Hanefeld reported of a girl with infantile spasms and hypsarrhythmia in early 
life [58] who later developed many characteristics of Rett syndrome; he thus firstly described 
the “early-onset seizure variant of RTT syndrome” that was later named the Hanefeld variant 
of RTT. Goutieres and Aicardi described two additional cases with early and intense seizure 
activity followed by rapid and profound behavioral deterioration [67]. In one of those 
patients, the seizures were reminiscent of infantile spasms. The RTT Hanefeld variant 
presents a phenotypic overlap with West syndrome, also known as X-linked infantile spasm 
syndrome (ISSX; OMIM 3083350), which is characterized by the triad of infantile spasms, 
hypsarrhythmia, and severe to profound mental retardation. In 2003, Vera Kalscheuer et al. 
characterized 2 unrelated female patients with a similar phenotype, comprised of severe early-
onset infantile spasms with hypsarrhythmia and profound global developmental arrest. The 
two patients showed an apparently balanced translocation where the X-chromosomal break-
points disrupted CDKL5 in both patients. Subsequently, several groups screened for CDKL5 
mutations in patients with both classic and atypical variants of RTT, but mutations were 
identified only in patients with seizure onset before 6 months of age [68,66,61]. 
The CDKL5 gene was initially identified through a positional cloning study aimed at isolating 
disease genes mapping to Xp22. Sequence analysis revealed homologies to several serine-
threonine kinase genes and identified one protein signature specific for this subgroup of 
kinases, hence the gene was named STK9 [69]. Moreover, since the kinase has a strong 
similarity to some cell division protein kinases [70], the STK9 gene subsequently appeared as 
CDKL5/STK9 and, eventually, got renamed CDKL5. 
 
 
Clinical Features 
 
The central features of the CDKL5 related phenotype include the early onset epileptic 
encephalopathy with seizures starting within the fifth month of life, severe developmental 
delay, deceleration of head growth, impaired communication and, often, hand stereotypies 
resembling those observed in RTT. Several dozens of girls and a few boys with CDKL5 gene 
mutations, or genomic deletions, have been reported, who were all having early-onset seizures 
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that in many cases were drug resistant.  
Reports suggested that several of the distinctive clinical features of Rett syndrome are lacking 
in CDKL5 related disorders; for instance, girls with CDKL5 mutations do not exhibit a clear 
period of regression, neither do they present the intense eye gaze and impaired 
neurovegetative function such as breathing disturbances, cold extremities and gastrointestinal 
disturbances, typically seen in girls with classic RTT. Patients with CDKL5 gene 
abnormalities are reported to be normal in the first days of life and subsequently exhibit early 
signs of poor developmental skills, including poor sucking and eye contact, even before 
seizure onset. Subsequently, absence of purposeful hand use, severe developmental delay, and 
lack of language skills become apparent [61,71,72,73,74,5,75]. About one third of patients 
will eventually be able to walk [71]. The typical neurological involvement in the Hanefeld 
variant of RTT is an epileptic encephalopathy with infantile spasms starting between the first 
days and fourth month of life [71]. Patients show a peculiar seizure pattern with ‘‘prolonged’’ 
generalized tonic-clonic events, lasting 2–4 min, consisting of a tonic-vibratory contraction 
followed by a clonic phase with series of spasms, gradually translating into repetitive distal 
myoclonic jerks [75]. Further studies of children older than 3 years showed that about half of 
them can experience seizure remission, whereas the remaining continue to have intractable 
spasms, often associated with multifocal and myoclonic seizures [71,74]. Early EEG findings 
vary from normal background to moderate slowing, with superimposed focal or multifocal 
interictal discharges and, in some cases, suppression burst pattern [75]. Although no specific 
seizure semiology has been described, two individual reports have noted a seizure pattern that 
may be unique to this disorder [75,76]. In one report a seizure pattern of tonic-tonic/vibratory 
contraction was observed, followed by a clonic phase with spasms and finishing with distal 
myoclonus [76]. In another report an initial hypermotor phase was seen, followed by tonic 
extension and then spasms.   
Whereas MECP2 mutations are rarely found in males, Liang et al. estimated that, in cohort of 
patients affected by epileptic encephalopathy, CDKL5 mutations have a frequency of 5% in 
males and 14% in females [77]. Males with CDKL5 mutations have in some cases been 
described as being more severely affected than girls; in fact, it has been reported that few of 
them learned to walk and few acquired spoken communication and hand function. Moreover, 
seizure onset was slightly earlier than in females, and all males were having either daily or 
monthly seizures [78]. Altogether, this suggests that an amelioration of the phenotype in 
females might be explained by X-inactivation in females resulting in a mosaic expression of 
normal, and mutant CDKL5 protein. However, a study describing a male with Klinefelter 
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syndrome (47,XXY) and a large CDKL5 COOH-truncation presenting a phenotype 
comparable to those of other CDKL5-positive boys suggests that the presence of a wild-type 
CDKL5 allele and a balanced pattern of X inactivation does not reduce the severity of the 
disease [79]. In RTT, males with mutations that cause classic RTT in females tend to be 
extremely affected, often dying at an early age due to severe infantile encephalopathy; in 
some cases males are mildly affected and have been found to have hypomorphic MECP2 
mutations that are not found in females [80]. It would be of interest to further investigate the 
genetic variability between males and females with CDKL5 disorders to determine whether a 
similar phenomenon exists.  
Together with the aforementioned phenotypes in CDKL5 patients, it has been proposed that, 
contrary to classic RTT, the CDKL5 disorder can be associated with distinct subtle facial, 
limb and hand phenotype that may assist in its differentiation from other early-onset 
encephalopathies. Although mutations in CDKL5 have been described in association with the 
early-onset variant of RTT, the majority of the patients do not fulfill the criteria for RTT [78]. 
According to the criteria established by Neul et al. for atypical RTT, five specific items 
(early-onset seizures before 5 months of age, infantile spasms, refractory myoclonic epilepsy, 
seizure onset before regression and decreased frequency of typical RTT features) were 
included that differentiate the ESV (early-onset seizure variant) from other atypical forms [5].  
In particular, the period of regression, which is a necessary criterion for RTT, is often absent 
in patients with CDKL5 mutations. Altogether, the CDKL5 disorder is now started being 
considered separate to RTT, rather than another variant of this syndrome.  
 
 
Structure of the CDKL5 gene and its protein isoforms 
 
The human CDKL5 (Gene bank accession number Y15057) gene occupies approximately 240 
kb of the Xp22 region and is composed of 24 exons. The first three exons (1, 1a, 1b) are 
untranslated and probably represent 2 transcription start sites, whereas the coding sequences 
are contained within exons 2-21. Two splice variants with distinct 5’UTRs have been found: 
isoform I, containing exon 1, is transcribed in a wide range of tissues, whereas the expression 
of isoform II, including exons 1a and 1b, is limited to testis and fetal brain [70,81]. An altered 
C-terminal region characterizes these two isoforms as depicted in figure 4. Importantly, one 
of these (CDKL5107) is common in a number of species, including mouse. Interestingly, an 
alternative splice variant, containing yet another distinct C-terminus, has been predicted 
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through a bioinformatics simulation but its existence still needs to be revealed [82].  
Moreover, in rats, 2 splice isoforms named CDKL5a and CDKL5b (GenBank accession 
numbers: FJ807484 and GU351881) corresponding to predicted proteins of 934 and 877 
amino acids, respectively, have also been identified [83]. While CDKL5a appears to be the 
major isoform in pure neuronal cultures, CDKL5b is the only form present in pure glial 
cultures suggesting a function in gliogenesis.  Recently, a novel and highly conserved 123-bp 
exon was identified between exons 16 and 17, referred as CDKL5 exon 16b [84] or CDKL5 
exon 16a [85]; the inclusion of the encoded 41 amino acids seems to occur specifically in the 
brain [84]. 
 
 
 
 
 
Figure 4: Genomic structure of CDKL5 and its splice variants. (a) The human CDKL5 gene 
with non-translated sequences in grey and exons encoding the catalytic domain in blue. Exons 
encoding the common C-terminal region appear in white, whereas isoform-specific sequences 
are shown in red, green, and as hatched. (b) hCDKL5 protein isoforms differing in the C-
terminal region. CDKL5115 [45] contains the primate-specific exons 19–21. In CDKL5107 
[81], intron 18 is retained. The inclusion of exon 16b would generate CDKL5115+ex.16b and/or 
CDKL5107+ex.16b [84,85]. hCDKL5−ex19 is a hypothetical splice variant in which exon 19 is 
excluded generating an alternative C-terminus (light blue) (c) The murine CDKL5 isoforms. 
mCDKL5105 harbors a distinct C-terminal region encoded by a mouse-specific exon 19 
(orange). As in humans, the retention of intron 18 generates the common CDKL5107 isoform 
[81]. Adapted from Kilstrup et al. 2012 [82]. 
 
The originally identified human CDKL5 is a large protein of 1030 amino acids with an 
estimated molecular mass of 115 kDa [86]. Initially, Montini et al. suggested that CDKL5 is a 
	   27	  
putative proline-directed serine/threonine kinase (due to the presence of a critical arginine-
residue in the kinase subdomain VIII), which is closely related to p56 KKIAMRE and p42 
KKIALRE (encoded by CDKL2 and CDKL1, respectively) that share homology with 
members of the mitogen-activated protein (MAP) kinase and cyclin dependent kinase (CDK) 
families [69]. The sequence analysis of the CDKL5 protein showed 2 kinase signatures in the 
catalytic domain: an ATP-binding region (amino acids 13-43) and a serine-threonine protein 
kinase active site (amino acids 131-143). Moreover, CDKL5 is characterized by a Thr-Xaa-
Tyr motif (TEY) at amino acids 169-171, whose dual phosphorylation is normally involved in 
activating, among others, kinases of the MAP kinase family. CDKL5 appears to be capable of 
auto-phosphorylating its TEY motif like some other MAPKs [86]. Additionally, CDKL5 is 
unique in this family of kinases as it displays an unusual long tail of more than 600 amino 
acids without obvious similarity to other protein domains but with a high degree of 
conservation between different CDKL5 orthologs that differ in the most extreme C-terminus. 
Moreover, putative signals for nuclear import (NLS) and export (NES) are present in the C-
terminus of the protein as depicted in figure 5.  
As mentioned above, recently, a new 107-kDa isoform with an alternative C-terminus that 
terminates in intron 18 was identified [81] and appeared to be the major isoform in human 
brain and all other tissues investigated except testis [81]. 
 
 
 
 
 
Figure 5: Schematic illustration of full-length human CDKL5 of 1030 amino acids 
containing the ATP binding site, the serine/threonine (S/T) kinase active site and the 
conserved Thr-Xaa-Tyr (TEY) motif within the catalytic domain. A putative signal peptidase 
I serine active site, 2 supposed nuclear localization signals (NLS) and one supposed nuclear 
export signal (NES) are indicated. The number on the top refers to the amino acids positions. 
Adapted from Kilstrup et al., 2012 [82] 
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Mutations in the CDKL5 gene and their influence on the phenotypic 
outcome 
 
The CDKL5-related disorder is an X-linked dominant disorder. Almost all the described cases 
are simplex cases (i.e., a single occurrence in a family), resulting from a de novo mutation 
except 1 familial case with 3 affected individuals [65]. The diagnosis of the CDKL5-related 
disorders relies on molecular genetic and cytogenetic testing. Though, the overall frequency 
of CDKL5 mutations in females with early-onset seizure is around 8-16% [62,73,74], the 
CDKL5 mutation rate is higher (28%) in female patients with early-onset seizures combined 
with infantile spasms [62]. 
Approximately 100 different CDKL5 patients, harboring a wide range of pathogenic 
mutations have been described so far, including missense and nonsense mutations, 
frameshifts, deletions (small and large), and aberrant splicing as described in figure 6. Albeit 
the small number of cases does not allow to draw any conclusive data, hot-spots have been 
suggested so far only for few mutations such as A40V, 172N/T, R178P/W/Q (Figure 6). The 
mutations are spread all over the coding sequence of CDKL5 with missense mutations found 
almost exclusively in the catalytic domain, thus confirming the relevance of the kinase 
activity of CDKL5 for proper brain functions. The missense mutations seem to reduce the 
kinase activity of CDKL5 [86]. Indeed, observations suggest that mutations in the catalytic 
domain of CDKL5 cause impairment in auto-phosphorylation and phosphorylation of target 
proteins such as MeCP2 [64,86]. On the contrary, truncating mutations can be located 
anywhere in the gene, leading to CDKL5 derivatives of various lengths. Again, the relevance 
of the rather uncharacterized C-terminal part of CDKL5 is suggested by the fact that many 
pathogenic alterations involve the C-terminus. Even though, so far, no reports have 
demonstrated the existence of the truncated CDKL5 proteins in human cells, the molecular 
effects of some pathogenic CDKL5 mutations (missense and truncating derivatives in the 
background of the CDKL5115 isoform) have been addressed through the overexpression of 
mutated derivatives in non-neuronal cell lines [87,86,88]. A regulatory role of the tail of 
CDKL5 has emerged from the characterization of few C-terminal truncating derivatives that 
have enhanced kinase activity and a constitutive nuclear accumulation [89]. It thus seems to 
act as a negative regulator of the catalytic activity of CDKL5 and to modulate the subcellular 
localization. In particular, since both the pathogenic derivatives L879X and R781X confine 
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CDKL5 to the cell nucleus, it can be assumed that the very last portion of CDKL5 contains a 
signal localizing the protein to the cytoplasm. However, since the leucine-rich NES-like motif 
indicated in Figure 6 is preserved in the L879X derivative, such motif seems insufficient for 
driving CDKL5 to the cytoplasm. Further studies have to be carried out to evaluate whether, a 
significant reduction of the catalytic activity of CDKL5 influences its subcellular distribution 
and the truncated CDKL5 mutants act as a loss or gain of function as well. 
 
 
 
     
 
 
 
Figure 6: Pathogenic CDKL5 mutations. All mutations in CDKL5 reported to date are 
indicated corresponding to their location within the gene. Mutations shown above the CDKL5 
gene are deletion and frame shift mutations as well as splice variants indicated with cDNA 
nomenclature. Missense and nonsense mutations (fuchsia and black, resp.) are represented 
with amino acid nomenclature below the CDKL5 gene. *: Recurrent mutations; ◦: Uncertain 
pathogenicity. Modified from Kilstrup et al., 2012 [82]. 
 
Interestingly, also duplications of larger genomic regions including, among other genes, 
CDKL5 have been identified [90,91,92], suggesting that a tight regulation of CDKL5 levels 
and/or activity is essential for the proper function of the nervous system. This hypothesis, if 
confirmed by further studies, will also have implications for gene therapy approaches. 
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CDKL5-Genotype-phenotype correlation 
 
There is a versatile range of phenotypes associated with CDKL5 mutations, including a milder 
form, where the epilepsy is controlled and independent ambulation is achieved, to a severe 
form with microcephaly, virtually no motor development and refractory epilepsy. The 
severity is determined by the protein product of the mutated allele of CDKL5 along with the 
variability of X-chromosome inactivation. The limited number of patients does not permit 
drawing any genotype-phenotype correlation yet; however, some reports suggested that 
mutations in the COOH-terminus contribute to a milder clinical picture compared to 
mutations in the catalytic domain. Additionally, it was also reported that patients with stop 
codon mutations have a milder phenotype than those with missense or splicing mutations 
[93], whereas others state that the nature of the mutation does not correlate with the clinical 
heterogeneity. It is well known that the CDKL5 gene is subject to X-chromosome inactivation 
(XCI). Therefore, skewed patterns of inactivation could explain phenotypic variability in 
females heterozygous for a mutated allele. For instance, Kalscheuer and colleagues reported 
some females with very severe phenotypes who carried X; autosome translocations, where the 
normal X chromosome was completely inactivated [70]. Conversely, Weaving et al. described 
two twin sisters exhibiting significant discordant phenotypes but with similar XCI pattern 
[65]. One proband showed a clinical phenotype overlapping with RTT while her twin sister 
showed autistic disorder and mild to moderate intellectual disability. The phenotypic 
differences in these two girls thus cannot be attributed to different degrees of XCI and an 
alternative explanation proposed that modifier genes might have influenced the disease 
severity.  
 
 
Expression pattern, localization and functional consequences of CDKL5 
 
Expression studies in human and mouse tissues have shown that CDKL5 mRNAs can easily 
be detected in tissues such as testis, lung, spleen, prostate, uterus, and placenta but the levels 
are highest in brain, whereas they are hardly present, or under detection levels in heart, 
kidney, liver, and skeletal muscles. In the brain, CDKL5 levels reach a plateau in conjunction 
with the development and differentiation of this organ. In situ hybridization analysis of adult 
mouse brain revealed that the mRNA levels are particularly high in the adult forebrain, 
especially in the most superficial cortical layers particularly involved in the connection of the 
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two hemispheres through the corpus callosum. The higher abundance of Cdkl5 mRNA in 
frontal cortical areas might suggest a role of the kinase in the physiology of such brain 
districts. The other brain areas such as motor cortex, the cingulate cortex, and pyriform 
cortex, possibly, in entorhinal cortex, also show significantly high levels of Cdkl5 mRNA. 
Additionally, very high levels of CDKL5 mRNA are detected in all the cornu ammonis (CA) 
regions of hippocampus compared to dentate gyrus (DG). Since the striatum also shows fair 
expression levels of CDKL5, it is assumed that the glutamatergic and gabaergic neurons are 
by far the two cellular types expressing most of the brain CDKL5. Comparatively, very low 
levels of CDKL5 are found in the dopaminergic areas such as substantia nigra or the ventral 
tagmental area, and the noradrenergic areas such as the locus coeruleus. Interestingly, in 
several thalamic nuclei, including the geniculate nuclei, the CDKL5 level is quite high. In the 
cerebellum, CDKL5 mRNA is found in all the lobules and, possibly, in the Purkinje cells; its 
levels, however, appear significantly lower than the other brain areas.  
Protein expression analyses have shown that the levels of the kinase more or less coincide 
with its transcripts in the developing and adult brains. During brain development, CDKL5 
expression is very low in abundance in the embryonic cortex and is strongly induced in early 
postnatal stages where it reaches maximum levels at P14 and then declines slowly up to adult 
stages. Additionally, in the cerebellum, the expression of CDKL5 appears to be induced 
slightly later and continues to increase until adult stages [89]. Immunohistochemistry 
experiments in human adult brains revealed numerous and diffusely CDKL5-positive cells in 
both cerebral cortex and corpus callosum with a general pattern very similar to that observed 
in the adult mouse brain. Rusconi and colleagues showed that CDKL5 is easily detectable in 
virtually all NeuN-positive neurons while it is expressed at very low levels in the glia [89]. It 
was also observed that CDKL5 is found in the majority of the neuronal fraction regardless the 
neural origin; however, some neurons display increased levels of CDKL5, particularly in the 
dentate gyrus (DG). GABAergic cortical interneurons within the hilus express CDKL5 much 
stronger than the dentate granular neurons. Additionally, CDKL5 levels were observed 
comparatively higher in GABAergic neurons than glutamatergic neurons [89]. Furthermore, 
in the human cerebellum, CDKL5 is present in the majority of the cells corresponding to 
granular, molecular, and Purkinje cell layers, although increased levels were present in 
Purkinje neurons [89]. Therefore, the different CDKL5 expression patterns in different 
neuronal populations suggest that a strict control of CDKL5 levels is required to regulate 
specific neuronal activities.  
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Regulation of CDKL5 expression 
 
As mentioned, the levels of Cdkl5 transcripts vary during development and in the different 
brain regions. Presently, little is known regarding the regulation of Cdkl5 at the transcription 
level but 2 CpG islands (CGI) have been found upstream and downstream of the 
transcriptional start site that are conserved among mouse and human counterparts. The 
conservation and position of these CGIs suggest their possible involvement in the epigenetic 
regulation of CDKL5 expression based on DNA methylation. Accordingly, Cdkl5 expression 
was found to be silenced by DNA methylation, involving this area, and by the action of 
MeCP2 [94]; earlier reports, however, showed that CDKL5 mRNA levels are unaltered in 
RTT patients’ lymphocytes or brains of Mecp2-null mice [65,45]. Therefore, more studies are 
required to confirm a role of MeCP2 in inhibiting CDKL5 expression. Notably, Carouge et al. 
demonstrated that Cdkl5 transcription appears to be regulated by different stimuli and 
depending on the specific brain areas; in the striatum of rats treated with cocaine (a pro-
methylation agent), Cdkl5 mRNA levels were found significantly reduced (probably as a 
consequence of methylation at the 5’ of the Cdkl5 gene), whereas this reduction was not 
noticed in frontal cortices of the same animals [94]. 
Several mechanisms seem to regulate CDKL5 functions and levels. The presence of various 
CDKL5 splice variants in the brain indicates that alternative splicing is involved in regulating 
CDKL5 functions; however, the distinct functions of different splice variants are still under 
consideration. The difference that has been observed so far is that CDKL5107 appears to be 
more stable than the longer human CDKL5115 isoform [81], whereas the subcellular 
localization of exogenous CDKL5 derivatives (CDKL5115, CDKL5107, and CDKL5115+16b) is 
grossly identical [81,84]. CDKL5 functions seem to be regulated both through its subcellular 
localization and through its synthesis and degradation. The kinase is present in both nucleus 
and cytoplasm of cultured cortical neurons and in different neurons throughout the brain. In 
some regions of the brain such as hippocampus, cortex, hypothalamus, and thalamus, CDKL5 
is almost equally distributed in cytoplasm and nucleus (around 40% of the protein is nuclear), 
whereas in the striatum and cerebellum, the cytoplasmic fraction accounts for almost 80% of 
CDKL5, suggesting that the difference in specific distribution of the protein between the two 
main cellular compartments must play a pivotal role in brain development. In late embryonic 
and early postnatal stages, CDKL5 is predominantly present in the cytoplasm with less than 
20% of the protein being present in the nucleus. It gets progressively accumulated in the 
nucleus starting from roughly P14, indicating that there are some regulatory mechanisms 
	   33	  
modulating the subcellular localization of CDKL5 in murine brain development [89]. In the 
nucleus, endogenous CDKL5 can be observed in nuclear clusters that have recently been 
demonstrated to correspond to the small nuclear ribonuclear protein complexes [95], linking 
the kinase to the complex machinery of RNA processing. Exogenous CDKL5 shuttles 
constitutively between the two main compartments in cultured non-neuronal cells through an 
active nuclear export-dependent mechanism involving the C-terminus of the protein and the 
CRM1 nuclear export receptor. Interestingly, however, in resting hippocampal neurons, the 
endogenous protein is not dynamically shuttling and its nuclear exit appears to be regulated 
by specific stimuli. In fact, glutamate treatment induces nuclear export of CDKL5 leading to 
its accumulation in the cytoplasm, suggesting that specific stimuli determine the shuttling of 
the kinase between the cellular compartments. It would be quite interesting to understand 
whether (a) posttranslational modifications or interactions with other proteins are involved in 
regulating the nuclear export/import of CDKL5, (b) the enzymatic activity of the protein is 
modulated by its localization and interaction with other factors, and eventually (c) with other 
stimuli influence the localization and activity of CDKL5.  
CDKL5 functions seem to be regulated through its degradation under certain stimuli such as 
sustained glutamate treatment or other cell death signals but how the regulation of this 
degradation occurs and its significance for cell death/survival are still unknown. Williamson 
and colleagues demonstrated that the CDKL5107 isoform is more stable, while CDKL5115 is 
rapidly degraded in a proteasome-dependent manner in transfected cells, indicating that the 
very C-terminal region, from amino acid 905, contains signals responsible for this 
degradation [89].  
 
 
CDKL5 involvement in neuronal morphogenesis, synaptic function, 
structure and plasticity 
 
Although little is still known about the neuronal functions of CDKL5, an accumulating body 
of evidence suggests that the kinase is involved in the processes related to the regulation of 
gene expression and neuronal morphogenesis [83]. As mentioned, in neurons CDKL5 is 
present both in the nucleus and in the cytosol [89] where it interacts with several specific 
proteins and, therefore, the study of these interactions would provide information regarding 
the functions of CDKL5, the signaling pathways in which it might be involved and, finally, 
the relationship between CDKL5 mutations and the pathogenesis of the neurological disorders 
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caused by mutations in this gene. 
As mentioned in the previous section, endogenous CDKL5 shows a diffuse staining with 
brilliant nuclear dots that do not overlap with heterochromatic DAPI-positive DNA in the 
nuclear compartment of cycling cells and primary hippocampal neurons [86,96], while the 
cytosolic CDKL5 immunostaining is finely dotted in both the soma and along the dendrites. 
Likewise, in adult mouse brain the punctate pattern of CDKL5 immunoreactivity is evident in 
cell bodies, along dendrites and in synaptic spines [97]. 
In the nucleus, CDKL5 has been found to interact with various proteins/factors and, in 
particular, several pieces of evidence suggest that CDKL5 belongs to the same molecular 
pathway as MeCP2. Mari and colleagues revealed that CDKL5 interacts with MeCP2 and is 
capable of phosphorylating the protein in vitro [45]. Moreover, the two proteins share a 
common spatial and temporal expression profile and, therefore, it can be speculated that 
CDKL5 may regulate MeCP2 functions through its post-translational modification. The loss 
of this phosphorylation dependent activity of MeCP2 might explain the presence of a subset 
of RTT like symptoms in patients with CDKL5 mutations whereas the distinct symptoms 
characterizing CDKL5 disorders would be caused by MeCP2-independent functions of the 
kinase.  However, the influence of CDKL5 in determining the phosphorylation state of 
MeCP2 in vivo is still unclear. Some reports revealed two more interactors of CDKL5 in the 
nucleus, both involved in the regulation of gene expression. One is DNA methyltransferase 1 
(DNMT1), an enzyme that recognizes and methylates hemimethylated CpG after DNA 
replication. In vitro, a truncated CDKL5 derivative, containing only the catalytic domain, 
binds and phosphorylates DNMT1 in the N-terminal region in the presence of DNA; 
however, further studies are required to confirm whether also full length CDKL5 associates 
with DNMT1 in vivo [98].  Considering the interaction of CDKL5 with DNMT1 and MeCP2, 
it can thus be speculated that CDKL5 may regulate the functions of epigenetic factors and 
transcriptional regulators. Another proposed interacting protein, the SR-family splicing factor, 
SC35, was found to co-localize with CDKL5 in the neuronal nuclear speckles both in vitro 
and in vivo and to co-immunoprecipitate with the kinase [95]. Interestingly, in vitro splicing 
assays indicated that some splicing deficits might be caused by the loss of CDKL5. 
As mentioned, the expression pattern of CDKL5 correlates both in vitro and in vivo, with 
neuronal maturation; in fact, the protein reaches the highest levels of expression when 
neurons acquire a mature phenotype, suggesting an involvement of the kinase in neuronal 
differentiation and arborization [83,89,96]. Some of the CDKL5 dendritic punctae were found 
to localize to dendritic spines where a significant co-localization with PSD95 (post-synaptic 
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density protein 95) could be determined [97]. Consistent with the postsynaptic localization, 
CDKL5 immunolabelling was closely juxtaposed with presynaptic VGLUT1. Conversely, 
CDKL5 was also found to co-localize marginally with inhibitory synaptic markers, indicating 
that the majority of CDKL5 is localized at excitatory synapses both in vitro and in vivo [97].  
It is well established that PSD-95 plays an essential role in synapse development and function 
by acting as the major scaffolding protein in the post-synaptic densities [99]. In excitatory 
synapses, PSD-95 associates with neurotransmitter receptors, adhesion molecules, and 
signaling enzymes, and its synaptic clustering precedes any of these associated partners, 
suggesting that it functions as an organizer to initiate synapse maturation. Recently, it was 
found that the N-terminal region of PSD-95 interacts efficiently with CDKL5 [100]. 
Interestingly, the palmitoylation of N-terminal residues of PSD-95 is necessary for the 
association with CDKL5. PSD-95, as any palmitoylated proteins, undergoes consecutive 
cycles of palmitoylation and depalmitoylation. In particular, the depalmitoylation of PSD-95 
is accelerated by glutamate receptor activation, whereas palmitoylation is increased by 
blocking synaptic activity or by BDNF stimulation [101]. Palmitate cycling on PSD-95 
controls its polarized targeting to synapses, which is essential for its synaptic functions [102]. 
Mutations within PSD-95 that interfere with palmitoylation reduced the synaptic targeting of 
CDKL5, suggesting that PSD-95 recruits the kinase to the synapses. Furthermore, some 
truncating disease causing mutations of CDKL5 abolish the association with PSD-95 
suggesting a mechanistic insight to some cases of CDKL5-related disorders [100].  
In accordance with the localization of CDKL5 at the excitatory synapses it has been shown 
that CDKL5 participates in the regulation of excitatory dendritic spine development and 
dendritic morphogenesis. In the excitatory synapses, CDKL5 also interacts with NGL-1 
(Netrin-G1 Ligand 1), a transmembrane protein localized in the post-synaptic densities (PSD) 
[97]. NGL-1 specifically interacts with Netrin-G1, a lipid-anchored protein related to the 
netrin family of axon guidance molecules, and promotes the early synapse formation and 
subsequent maturation [103]. Among PSD-enriched proteins, the three components of the 
NGL-family (NGL-1, NGL-2 and NGL-3) were identified as CDKL5-interacting partners. 
Interestingly, CDKL5 was found to phosphorylate NGL-1 in vitro on Ser 631 and this 
phosphorylation event seems to strengthen the interaction between NGL-1 and PSD95 [97]. 
In line with a role of CDKL5 for synapse functions, dendritic spine morphogenesis and 
synaptic activity has been found altered in neurons devoid of CDKL5. Neurons depleted for 
CDKL5 showed a significant increase in protrusion density with dendritic protrusions being 
significantly thinner when compared with controls and showing a filopodia-like morphology. 
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Some of these thin filopodia-like spines were particularly branched and exhibited an aberrant 
morphology. Furthermore, the percentage of filopodia-like spines and thin-headed spines 
increased, whereas the percentage of stubby and mushroom-shaped spines decreased. These 
observations indicate that CDKL5 is required for ensuring a correct number of well-shaped 
spines, correct dendritic spine structure and synapse activity. In agreement with the in vitro 
studies, also the depletion of Cdkl5 in cortical pyramidal neurons in vivo by in utero 
electroporation (IUE) of mouse embryonic cortices generated a significant decreased density 
of VGLUT1 puncta in excitatory presynaptic buttons, confirming that CDKL5 is crucial for 
dendritic spine morphogenesis and synaptic contact maintenance also in vivo [97]. Given that 
CDKL5 is a protein kinase, its phosphorylation activity is likely to play an important role for 
neuronal functions. Studies with a kinase-dead CDKL5 derivative, CDKL5-K42R that is 
unable to bind ATP, confirm this hypothesis: Primary neurons overexpressing CDKL5-K42R 
exhibited a significantly high number of thinner and longer dendritic protrusions and a 
corresponding loss of stubby and mushroom-shaped spines. As the phenotype discovered for 
the CDKL5-K42R mutant was similar to the phenotype of CDKL5 knock-down neurons, it is 
conceivable that CDKL5 promotes spine formation through a mechanism that is dependent on 
its kinase activity and that the kinase-dead derivative acts as a dominant negative. 
In addition to a role in regulating dendritic spine formation, CDKL5 has also been found to 
regulate neuronal morphogenesis [83]. Indeed, shRNA mediated silencing of Cdkl5 in cortical 
neurons leads to a marked reduction in the total length of both dendrites and axons. The total 
dendrite length and the complexity of arborization were also reduced upon Cdkl5 depletion, 
indicating that the expression of the kinase in cortical neurons is required for dendritic 
arborization as well as dendrite growth. In vivo studies also confirmed that CDKL5 is 
required for dendritic arborization. Indeed, morphological analysis of layer II/III pyramidal 
neurons in cortices silenced for Cdkl5 by IUE showed that the silenced neurons were 
characterized by a marked reduction in both the total length of apical dendrites and number of 
apical dendrite branches. Moreover, the IUE studies revealed that the silencing of Cdkl5 in rat 
embryos at E15 causes migration defects that can be observed at P0. The migration was not 
altogether blocked but delayed, since at P14 the neurons had migrated into cortical layers and 
extended apical dendrites towards the pial surface. Neuronal migration disorders are 
characterized by abnormal neuronal positioning in the cerebral cortex, which have been 
implicated in infantile spasm and seizures. For example, mutations in the human doublecortin 
(DCX) and reelin (RELN) genes cause profound defects in cortical neuron migration, and 
patients with these mutations have severe mental retardation and epilepsy [104,105]. 
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Therefore, the delay in neuronal migration [83], caused by the loss of CDKL5, might be 
involved in the presence of seizures characterizing patients with CDKL5 mutations. 
According to the observations by Chen and colleagues [83], CDKL5 co-localizes with F-actin 
in the peripheral domain of growth cones, suggesting that CDKL5 might be involved in 
regulating actin cytoskeleton. Rac1 (Ras-related C3 botulinum toxin substrate 1), a small 
signaling G protein, which is a member of the Rho family, plays a crucial role in the 
regulation of cell growth and cytoskeletal reorganization and was found to mediate the effect 
of CDKL5. In COS-7 cells, the constitutively active form of Rac1 (CA-Rac1) forms a protein 
complex with CDKL5 and recruits the kinase to the membrane while a dominant negative 
form of Rac1 (DN-Rac1) failed to do so even under stimulation. In cultured neurons, Rac1 is 
activated by BDNF, a critical regulator of neuronal development and function. Moreover, 
BDNF stimulation was found to enhance the CDKL5 and Rac1 interaction directly or 
indirectly by formation of protein complex, and to trigger a transient increase in CDKL5 
phosphorylation, suggesting that CDKL5 is involved in BDNF-induced activation of Rac1 
and providing a reasonable explanation of the correlation between CDKL5 mutations and the 
observed defects in cognitive functions [83].  
Importantly, a Cdkl5 knock-out mouse model has recently been developed, mimicking a 
disease causing mutation that leads to a frame-shift and the premature truncation within the 
N-terminal kinase domain, thus generating a loss-of-function mutation. Male mice lacking 
Cdkl5 (Cdkl5–/y) and heterozygous females (Cdkl5−/+) were viable, fertile, and displayed 
normal appearance, growth, and overall brain morphology [106]. Interestingly, the mice 
exhibit hyperactivity, impaired motor control, decreased anxiety and some autistic-like 
behavioral abnormalities such as impairment in social interaction as well as impairment in 
learning and memory. Although this mouse model mimics well the autism spectrum features 
characterizing patients with CDKL5 deficits, the Cdkl5-null mice did not develop seizures and 
therefore does not fully mirror all the key-characteristics of humans with CDKL5 mutations. 
A possible explanation could be given by distinct functions or modifications of CDKL5 in 
humans that might be absent in lower organisms. Moreover, the C57BL/6 genetic background 
is known to confer increased seizure resistance [107], possibly explaining the absence of 
seizures in the knock-out mice. Interestingly, the male mice lacking Cdkl5 (Cdkl5–/y) exhibited 
a decrease in the phosphorylation profiles of various kinases that are involved in synaptic 
plasticity as well as in cellular metabolism, indicating that CDKL5 may play a critical role in 
coordinating multiple signaling cascades. In spite of lacking some characteristics of CDKL5 
related disorders in humans, this model has paved the way of future understanding of the loss 
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of CDKL5 for various neurological functions and represents a crucial tool for future studies of 
the involvement of CDKL5 for human pathologies. 
 
 
Neuronal polarization  
 
Neurons are among the most polarized cell types in our body and possess two types of 
morphologically and functionally distinct processes: a single, long, and slender axon and 
several dendrites that are shorter processes with a tapered morphology. During the 
transmission of neuronal information, dendrites integrate synaptic inputs triggering the 
generation of action potentials at the level of the soma and propagate along the axon making 
presynaptic contacts onto the dendrite of target neurons [108].  
Mammalian neurons usually migrate over a long distance before reaching their final 
destination. In vivo, most neurons undergo axon-dendrite polarization during migration where 
post-mitotic neurons form a leading and a trailing processes, which determine the axon or the 
dendrite depending on the cell type. For instance, the retinal ganglionic cells and bipolar cells 
in the developing vertebrate retina can inherit their axon and dendrite polarity directly from 
the apico-basal polarity of their progenitors whereas cerebellar granule neurons (CGN) as 
well as cortical and hippocampal pyramidal neurons (PN) undergo extensive stereotypical 
changes in their morphology that lead to a polarized outgrowth of their axon and dendrite. 
Importantly, both CGN and PN acquire their axon dendrite polarity from the polarized 
emergence of the trailing-leading processes during migration.  
So far, most studies on the establishment of neuronal polarity are performed on dissociated, 
embryonic cortical and hippocampal neurons or post-natal cerebellar granule neurons [108]. 
Cultured primary hippocampal neurons undergo several stages during polarization as 
described by Dotti and Banker [109] (Figure 7). When the dissociated hippocampal neurons 
are plated, neurons attach to their substrate as round spheres (stage1) surrounded by actin-rich 
structures, lamellipodia and filopodia. In stage 2, several minor immature neurites, emerge, 
thanks to the coalescing lamellipodia in some areas of the growth cone. One of these minor 
neurites starts growing rapidly to become an axon at stage 3, while other minor neurites 
remain short and develop into dendrites at stage 4. Ultimately, at stage 5, the cells undergo 
further maturations and establish a neuronal network through synaptic contacts between 
dendritic spines and axon terminals.  
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Figure 7: Schematic illustration showing the alteration of neuronal morphology during the 
process of polarization. Adapted from Arimura and Kaibuchi, 2007 [110]. 
 
The mechanisms underlying the specification of a single axon among equally potential 
neurites has been extensively studied in cultured hippocampal neurons. A large body of 
evidence suggests that neuronal polarization is largely specified by the stochastic, asymmetric 
activation of intracellular signaling pathways and that extracellular cues can play an 
instructive role during polarization in vitro and in vivo. A varied range of positive and 
negative signaling molecules control neurite extension and retraction. These molecules 
diffuse within neurites to regulate the behavior of cytoskeleton and or to influence cargo 
transport [111].  
During polarization, positive and negative signals seem to be intricately balanced. When this 
balance is broken by a positive cue, a continuous self-activation system (positive feedback 
loop) [112] is activated, through which a single minor process becomes an axon. 
Simultaneously, this self-activation system creates strong negative feedback signals that 
prevent other neurites from forming a second axon [111]. This scenario might fulfill the query 
of a single axon formation among equally potential neurites.  
During the accelerated outgrowth of the axon the differential organization of the cytoskeleton 
plays a fundamental role. In fact, before axonal outgrowth, the growth cone of the future axon 
increases in size and its actin cytoskeleton becomes more dynamic and less condensed, 
whereas the other growth cones remain rather static and retains a rigid actin cytoskeleton 
[113]. At the same time, the transient stabilization of microtubules occurs in the neurites of 
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the future axon. Altogether, the regulation of microtubule stability and actin dynamics plays a 
fundamental role in the process of neuronal polarization. 
 
 
Shootin1 and axon outgrowth 
 
Shootin1 (KIAA1598) has in the last years been described as a key factor for neuronal 
polarization by providing the asymmetric signal initiating this process. In 2006, Toriyama and 
colleagues identified a novel brain specific intracellular protein, shootin1 (KIAA1598) in a 
screen for proteins that get induced during neuronal polarization [114]. Shootin1 encodes a 
protein of 456 amino acids and belongs to a novel class of proteins that contains three coiled-
coil domains and a single proline-rich region. The expression of shootin1 gets upregulated 
during the period of axon formation and elongation, both in hippocampal neurons and in 
brain, suggesting its involvement in refining neuronal morphology.   
In young non-polarized stage 2 neurons, shootin1 is diffused in the cell body but in the phase 
of stage 2 the relative concentration of shootin1 changes and the protein accumulates in a 
single neurite right before its accelerated outgrowth leading to axon formation. The active 
transport of shootin1 from the soma to the distal tip has been found dependent on KIF20B 
whereas its retrograde movement is by passive diffusion [115]. When the anterograde 
transport of shootin1 is inhibited, its asymmetric accumulation gets disturbed and axon 
formation is impaired. The involvement of shootin1 for axon formation has been further 
demonstrated by the fact that its overexpression causes the formation of multiple axons 
whereas its depletion causes a defect in neuronal polarization [114]. The aforementioned 
observations led to propose a model explaining the involvement of shootin1 in generating an 
asymmetric signal for neuronal polarization where its up-regulation triggers positive feedback 
and negative regulation (as depicted in figure 8) allowing the outgrowth of one axon only.  
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Figure 8: A proposed model for the involvement of shootin1 in generating an asymmetric 
signal for neuronal polarization. (A) A positive feedback loop between shootin1 accumulation 
in growth cone and shootin1-induced neurite elongation. (B) Competition among neurites for 
a limited amount of shootin1. (C) Shootin1 up-regulation triggers local positive feedback 
loops (red arrows) and negative regulations (blue arrows), shifting the symmetry of neurons 
from unpolarized to polarized state. Eventually, shootin1 gets asymmetrically accumulated in 
a single neurite and recruits PI3-kinase activity there, thereby leading to neuronal 
polarization. Adapted from Toriyama et al., 2006 [114]. 
 
Interestingly, shootin1 was found to interact with PI3-kinase regulating the spatial localization 
of the activity of this kinase in the axonal growth cone of hippocampal neurons [114]. PI-3 
kinase is located at an upstream position in the signaling pathways for neuronal polarization 
involving many molecules, such as phosphatidylinositol (3,4,5) triphosphate, the mPar3-
mPar6-aPKC complex, Cdc42, Rap1B, STEF/Tiam1, Rac, Akt, adenomatous polyposis coli, 
glycogen synthase kinase-3β, and collapsin response mediator protein-2 (CRMP2) [116,110]. 
By regulating the localization of PI3 kinase activity shootin1 thus seems to play a crucial role 
in axon formation [114].  
 
Recently, Toriyama and colleagues demonstrated that shootin1 is located at a critical interface 
that transduces a chemical signal into traction forces for axon outgrowth. A chemoattractant, 
netrin-1, triggers a signaling pathway activating a Cdc42 and Rac1 dependent up-regulation 
of Pak1 (p21-activated kinase 1) leading to shootin1 phosphorylation. Pak1 was found to 
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phosphorylate two sites, Ser101 and Ser249, within shootin1, causing an enhancement of the 
association of shootin1 with F-actin retrograde flow at the growth cones [117]. It has been 
proposed that “clutch” molecules regulate the coupling efficiency between F-actin flow and 
the extracellular substrate (figure 9). The Pak1-mediated phosphorylation of shootin1 thus 
seems to promote this clutch engagement and the concomitant formation of traction forces at 
axonal growth cones that lead to filopodium extension and axon outgrowth. 
 
 
    
 
 
 
 
Figure 9: A model for signal-force conversion for axon outgrowth. Netrin-1, via activation of 
DCC (netrin-1 receptor), Cdc42, and Rac1, induces Pak1-mediated shootin1 phosphorylation 
(black arrows), thereby enhancing clutch engagement through shootin1-F-actin interaction 
(blue arrow). Clutch engagement converts the F-actin flow (yellow arrows) into traction 
forces exerted on the substrate (green arrows). This engagement also reduces the speed of the 
F-actin flow, converting actin polymerization into protrusion of the leading edge (gray arrow). 
Clutch engagement (blue arrow) and Cdc42 and Rac1-induced actin polymerization (red 
arrows) may work coordinately to effectively regulate mechanical forces for cell motility. 
(Adapted from Toriyama et al., 2013 [117]) 
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MATERIALS AND METHODS 
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Yeast two-hybrid screening 
The yeast two-hybrid screening was performed by Hybrigenics Services, S.A.S, Paris, France 
(http://www.hybrigenics-services.com). The coding sequence for amino acids 299-1030 of 
human CDKL5 (GenBank accession number gi: 83367068) was PCR-amplified and cloned 
into the inducible pB35 vector as a C-terminal fusion to Gal4 DNA-binding domain (N-Gal4-
CDKL5-C). The construct was used as a bait to screen a random-primed Human Adult Brain 
cDNA library constructed into pP6.  
Using the Gal4 inducible construct, 113 million clones (11-fold the complexity of the library) 
were screened using a mating approach with Y187 (MATα Gal4Δ Gal80Δ ade2-101 his3 
leu2-3,-112 trp1-901 ura3-52 URA3::UASGAL1-LacZ, (met-)) and CG1945 (MATa Gal4-
452 Gal80-538 ade2-101 his3-D200 leu2-3,112 trp1-901 ura3-52 lys2-801 URA3::Gal4 
17mers (X3)-CyC1TATA-LacZ lys2::GAL1UAS-GAL1TATA-HIS3 cyhR) yeast strains. A 
total of 171 His+ colonies were selected on a minimal medium lacking tryptophan, leucine, 
methionine and histidine. The prey fragments of the positive clones were amplified by PCR 
and sequenced at their 5’ and 3’ junctions. The resulting sequences were used to identify the 
corresponding interacting proteins in the GenBank database (NCBI) using a fully automated 
procedure. A confidence score (PBS, for Predicted Biological Score) was attributed to each 
interaction as previously described [118]. 
 
 
Plasmids and constructs 
pCAGGS-Cdkl5-ires-GFP was cloned by inserting an EcoRI-EcoRV digested PCR product 
containing the murine Cdkl5 cDNA (NP_001019795) into pCAGGS-ires-GFP digested with 
EcoRI and SmaI. pCAGGS-shootin1-ires-GFP, encoding human shootin1 isoform 2 
(ABK56022) was generated in a similar way. Cdkl5-A40V mutant was generated by a PCR 
based method and cloned into pCAGGS-IRES-EGFP as wild-type Cdkl5. Lentiviral vectors 
to silence endogenous CDKL5 and shootin1 were generated by cloning double stranded 
oligonucleotides into the HpaI and XhoI sites of pLentiLox 3.7 (pLL 3.7). The target 
sequences of the shRNAs are as follows: shCDKL5#1: CTATGGAGTTGTACTTAA; 
shCDKL5#2: GTGAGAGCGAAAGGCCTT; shShootin1#1: 
5’CCACGGTGAATAAATAGAAAT (against the 3’UTR); shShootin1#2: 
GCAGAACCATCTTGAAATA; shShootin1#3: GCACAAGAGATGATCATTGAA, a 
shRNA against LacZ was used as control. All PCR derived constructs were sequence verified. 
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Virus preparation 
HEK293T cells, grown in 150 mm dishes, were co-transfected with the packaging vectors 
pVSV-G, pMDL, pREV and either pLL3.7-shCDKL5#1, pLL3.7-shCDKL5#2, pLL3.7-
shShootin1#1, pLL3.7-shShootin1#2, pLL 3.7-shShootin1#3 or pLL3.7-shLacZ using 
calcium phosphate. The viral particles were harvested 36 hours post-transfection and 
concentrated by ultracentrifugation with SW32 rotor (Beckman Instruments) at 20,000 rpm 
for 2 hours. The viruses were resuspended in PBS and stored at -80°C. 
 
 
Reagents and antibodies 
The following primary antibodies were used in immunofluorescence (cultured neurons), 
immunohistochemistry (brain sections), and in western blotting experiments: Anti-CDKL5 
(HPA002847, Sigma-Aldrich), chicken anti-GFP (A10262, Life Technologies), anti-PERK 
(9101S, Cell Signaling), anti-shootin1 (PA5-17167 Thermo; 3279 Cell Signaling), anti-Tau1 
(MAB3420, Millipore), anti-Tag1 (DHSB, University of Iowa), anti-Tuj1 (MMS-435P, 
Covance), anti-β-actin (A5441, Sigma-Aldrich), anti-MAP2 (ab24640, Abcam). A custom-
made immunopurified rabbit polyclonal anti-CDKL5 antibody (Covance Research Products 
Inc.) was used for co-immunoprecipitation experiments, which was raised against CDKL5 
amino acids 301-751 as described by Bertani et al. in 2006. DAPI and secondary Alexa Fluor 
anti-rabbit, anti-mouse and anti-chicken antibodies for immunofluorescence experiments were 
purchased from Life Technologies. HRP-conjugated secondary anti-mouse and anti-rabbit 
antibodies for Western blottings were obtained from Thermo Scientific. 
 
 
Animal and Tissue preparation 
Wild-type CD1 mice were purchased from Charles River Laboratories and maintained as a 
breeding colony. Animals were housed under standard conditions (12 h light/dark cycle). 
Successful mating of mice was identified by vaginal plugs, with noon on the day of plug 
appearance designated embryonic day (E) 0.5. Animals were killed by cervical dislocation 
under Avertin anesthesia (pregnant females) or cryo-anesthesia (neonatal mice). Embryos 
were rapidly removed and perfused with 4% paraformaldehyde diluted in PBS (phosphate 
buffer saline). Embryonic brains were post-fixed by immersion in cold (4 °C) 4% 
paraformaldehyde for 4–6 h (for immunofluorescence) or overnight for in-situ hybridization. 
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Brains were cryo-protected in cold-buffered sucrose (30% in 0.1 M sodium phosphate, pH 
7.0), frozen in optimum cutting temperature compound (Sakura Finetek, Torrance, CA), cryo-
sectioned at 12 μm, and mounted on Superfrost Plus slides (Thermo Fisher Scientific, 
Waltham, MA). Slides were stored at −20 °C until needed. 
 
 
In utero Electroporation (IUE) 
Wild type C57BL/6J pregnant mice were used for in utero electroporation experiments, which 
were purchased from Charles River, Italy. The day on which the vaginal plug was found, 
considered as embryonic day 0 (E0).  Briefly the pregnant mice were anesthetized with 
Avertin (mixture of 2,2,2-tribromoetahnol and tertiary amyl alcohol). After cleaning the 
abdomen with 70% ethanol, a 3-4-cm midline lapratomy was performed and then the uterine 
horns were exposed. Plasmids such as pLL3.7 shShootin1#1, pLL.3.7 shShootin1#2, pLL3.7 
shCdkl5#1 and pLL3.7 ShLacZ, were prepared by using Endofree Plasmid Kit (Qiagen, 
Hilden, Germany).  
Approximately 1μl of plasmid (1μg) containing fast green dye (Sigma) was injected through 
the uterus wall into the lateral ventricle of telencephalon of E13 and E14 embryos with a glass 
micropipette. Thereafter, a pair of 4-5 mm at the tip of forceps electrode was placed outside 
the uterus at the head position. Electroporation was performed by using the Gene Pulser Xcell 
main unit #165-2666, set at four repeats of 50 ms pulses of 40 V with an interval of 900 ms. 
then the uterine horns were repositioned in the abdominal cavity, and the abdominal wall and 
skin were sewed up with surgical sutures. Embryos were allowed to develop in utero for 
certain time points, such as E17, E18, P0 and P8. Brains were dissected, fixed overnight in 
4% paraformaldehyde (PFA) at 4°C and then placed in 30% sucrose prepared in 1XPBS for 
over night to settle down. Brains were frozen in OCT (Tissue-Tek) and sliced coronally at 12 
µm by cryostat (Leica CM1850).  
 
 
Brain extracts and Immunoprecipitation 
Proteins were extracted by homogenizing P7 mouse brain in lysis buffer (50 mM Tris-HCl pH 
7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.1% SDS, 2 mM sodium 
pyrophosphate, 1 mM sodium orthovanadate). The lysates were incubated on ice for 20 
minutes and centrifuged at 100,000g for 30 minutes at 4o C. The supernatant were taken out 
and incubated overnight at 4oC with 20ul of purified anti-CDKL5 or 2ul of anti-shootin1 or 
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unrelated IgGs as a negative control. The equilibrated protein-G agarose beads (in lysis 
buffer) were incubated with 5%BSA at 4oC on rotating wheel for 1 hour. The required amount 
of blocked beads was added to the incubated samples and the mixture was incubated again at 
4oC on rotating wheel for 2 hours. After washing with the lysis buffer, immunocmplexes were 
analyzed by SDS-PAGE.  
 
 
In Situ Hybridization  
12 μm slide-mounted cryostat sections were thawed and washed in PBS. Slides were fixed for 
30 min at room temperature in 4% paraformaldehyde in PBS. Samples were processed as 
follows: washed in PBS, H2O and then incubated 5 min in Sodium Metaperiodate (2.3% in 
H2O), 5 min in 20% Acetic Acid, 3 min in TrisHCl (0.1M pH 7.5) and 5 min in Sodium 
Tetraborate (1% in Tris HCl 0.1M pH 7.5); washed in H2O and PBS; incubated 5 min in PBS 
with Proteinase K (30mg/ml, Promega), 5 min in 4% PFA in PBS, washed in H2O. Tissues 
were then incubated in Pre-Hybridization Buffer (PHB) (prepared in solution containing salt 
solution (NaCl 2M, TrisHCl 0.089 M, Tris base 0.011 M, NaH2PO4 0.05 M, Na2HPO4 0.05 
M, EDTA 0.05 M), 50% formamide, H2O) for 4 minutes and hybridized with the diluted 
antisense riboprobes against mouse Cdkl5 (full length) and shootin1 (full length) in 
hybridization solution (50% Formamide, salt solution, 10% dextran sulfate, Denhards’s 1X, 
tween20 0.05%, tRNA 1mg/ml) at 55°C overnight. Next day, slides were washed twice for 1 
hour in pre-warmed PHB and twice for 1 hour in pre-warmed 0.5X Salt Solution at 55°C. 
After cooling to room temperature, tissues were washed twice in Buffer 1 (TrisHCl pH 7.5, 
NaCl pH 8 0.1M), incubated for 1 h in blocking solution (TrisHCl pH 7.5 0,1M, NaCl 0,1M, 
Roche blocking solution 1%, TritonX-100 10%) and overnight at 4°C with anti-digoxigenin 
(1:1000, Roche #11207750910) diluted in blocking solution. 
The third day, slides were washed in Buffer1 (4 times for 10 min) and then twice in Buffer 3 
(TrisHCl 0.1M pH 9.5, NaCl 0.1M) with Levamisole (1mM). To stain the samples, slides 
were incubated in BCIP-NBT (Millipore) that reacted with the Alkaline Phosphatase bound to 
the anti-digoxigenin antibody. Slices were eventually washed in 50%, 80%, 100% ethyl 
alcohol, 100% xylene and mounted with DPX (Leica). Tissues were kept at room temperature 
to dry and images were obtained under bright field microscope (Nikon Eclipse Ni-U) at 
different magnifications. 
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Primary neuronal cultures 
Primary hippocampal cultures were prepared from embryonic day 16 CD1 mouse embryos 
(E16), considering the day of the vaginal plug as E0, as described previously [99] and plated 
on poly-L-lysine coated dishes at different densities: 2x103/cm2 for immunostainings and 
10x104/cm2 for western blots. For overexpression studies, hippocampal neurons were isolated 
at E17 and transfected at DIV0 by nucleofection using the Amaxa Basic Neuron Small cell 
Number Nucleofector Kit following the manufacturer’s instructions. Infection of hippocampal 
and cortical neurons was performed by adding lentiviral particles to the neurons before 
plating. 
 
 
Immunohistochemistry (IHC) 
12 μm slide-mounted cryostat sections were thawed and washed in PBS. Single- and double-
label immunofluorescence were performed. Blocking solution, consisting of PBS with 0.2% 
Triton X-100 (PBS-T), 10% normal horse serum was applied to slides for 30 minutes. Slides 
were incubated overnight at 4 °C with primary antibodies [anti-shootin1 (1:100), anti-Tag1 
(1:50), and anti-GFP (1:1000)] in blocking solution, rinsed 3 times in PBS for 30 min, and 
then incubated for 1 h at room temperature with fluorescent secondary antibodies (Alexa 
Fluor, Invitrogen) in the same blocking solution. Sections were rinsed 3 times in PBS for 10 
min and counterstained with DAPI (0.01%, Invitrogen). Sections were then mounted in 
ProLong Gold Antifade reagent (Life Technologies), dried and the images were obtained 
under fluorescent microscope (Nikon Eclipse Ni-U) at different magnifications. 
 
 
Immunofluorescence (IF) 
E17 or E18 mouse hippocampal neurons were fixed with 4% para-formaldehyde, 4mM 
EDTA and 4% sucrose for 10 minutes at room temperature, washed twice with 1X PBS and 
kept at 4o C with 0.02% sodium azide in PBS until needed. The coverslips containing neurons 
were washed thrice with TBS (Tris Buffer Saline), permeabilized and blocked with 
permeabilization cum blocking solution (5% horse serum, 0.2% Triton-X100 in TBS) for 1 
hour at room temperature. The neurons were incubated in the same blocking solution with 
polyclonal anti-CDKL5 1:100, monoclonal anti-TAU1 1:5000, polyclonal anti-shootin1 
1:100, overnight at 4°C.  
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The next day, neurons were washed three times with TBS 1X followed by incubation with 
secondary antibodies (Alexa Flour; Invitrogen) for 1 hour at room temperature. Cells were 
rinsed in TBS 1X three times followed by addition of DAPI (4',6-diamidino-2-phenylindole; 
IF 300 nM; Invitrogen) for 5 minutes at room temperature. The samples were rinsed three 
times with TBS1X and mounted in ProLong Gold antifade reagent. After drying up, slides 
were kept at 4°C/20°C depending upon the requirement of acquisition of images.  
 
 
Two-dimensional isoelectric focussing (2D IEF) 
2.5x106 cortical neurons isolated from E16 mouse embryos were infected at DIV0 to silence 
Cdkl5 expression. At DIV7, cells were washed and lysed in UTC buffer (7 M urea, 2 M 
thiourea, 4% CHAPS). Approximately 200 μg of extract were loaded on 7 cm IPG DryStrips 
with a linear 4-7 pH gradient and isoelectric focusing was performed with an IPGphor II 
apparatus (GE Healthcare) according to the manufacturer’s instructions. Subsequent SDS-
PAGE was performed using 8% gels and proteins detected by Western blotting. Phosphatase 
treatment was done by adding 100 units of Lambda Protein Phosphatase (Lambda PP; New 
England Biolabs) to the extract diluted in 2 ml 0.1% SDS, 0.1 mM MnCl2, and 1x PMP-
buffer. After an over night incubation at 30°C the samples were concentrated with Ultracel 
10K centrifugal filters (Millipore) and subjected to isoelectric focusing. 
 
 
Cells medium and solutions 
DMEM: DMEM 1X (Invitrogen), Foetal bovine serum (FBS), 10% Euroclone), 
L-glutamine 200 mM (Euroclone), Penicillin/streptomycine 1X 
(Euroclone). 
DMEM-HS:  DMEM+Glutamax (Invitrogen), Horse serum (HS), 10%, L-glutamine 
200mM (Euroclone), Sodium pyruvate (Gibco). 
TRYPSIN-EDTA (Gibco),  HBSS (Gibco) 
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Analysis of the Yeast-Two Hybrid Assay results 
 
To understand in more details the neuronal functions of CDKL5 we decided to perform a 
yeast two-hybrid screening that should allow the identification of interaction partners and 
possible substrates of the kinase. 
Previous studies have shown that the C-terminal region of CDKL5, spanning amino acids 
299-1030, regulates CDKL5 activities and harbours the surface of interaction with MeCP2 
and DNMT1 [45,98]; altogether, this suggests that both upstream and downstream effectors 
might target the C-terminus to regulate CDKL5 functions. Therefore, we decided to use the 
unique C-terminus of CDKL5, comprised between amino acids 299 and 1030 (115 kDa 
CDKL5 isoform) as a bait to perform a yeast two-hybrid screening. Hybrigenics, a company 
located in S.A. Paris, France, which is highly specialized in performing high throughput yeast 
two hybrid screens and delivers the final list of interactors with a biological confidence score, 
was chosen to perform the screen.  
In the initial tests, this bait, when constitutively expressed, was found to be highly toxic to the 
cells. Consequently, it was decided to use an inducible vector to express the GAL4DBD –
CDKL5 fusion protein containing the bait, thus bypassing the toxicity. A human adult brain 
cDNA library, containing approximately 10 million independent clones, was screened. By 
testing more than 100 million clones, the complexity of the library was covered more than 10 
times and 171 positive clones were isolated.  
Although only little is known about the neuronal functions of some of the identified CDKL5 
interactors, the yeast two hybrid screening gave a major insight into the putative interactors of 
CDKL5 and its possible involvement in several cellular activities. Different degrees of 
confidence score were assigned to the interactors and only one, KIAA1598, which is also 
named shootin1, obtained the highest confidence score. Given the role of shootin1 in neuronal 
polarization and its high confidence score, we decided to elucidate the role of CDKL5 in 
neuronal polarization through its interaction with shootin1. 
 
 
Shootin1 is a novel interactor of Cdkl5 in vivo 
 
As described previously, shootin1 is a brain specific protein that plays an important role in 
axon specification and neuronal polarization [114]. A total of seven clones containing 
different but overlapping regions of shootin1 enabled us to map the central region of shootin1, 
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spanning amino acids 53-290, as the surface that interacts with the C-terminal region of 
CDKL5 (Fig 1 A). Previous studies determined that the level of shootin1 expression in rat 
brain is relatively low at embryonic day 15 (E15), gradually increases in early postnatal life, 
peaks at P4, starts decreasing at P14 [114] and is under detection level in the adult brain. 
Altogether this strongly indicates the involvement of shootin1 in early developmental stages 
of brain development. Conversely the expression of Cdkl5 correlates with neuronal 
maturation and the protein remains significantly expressed through adulthood [89]. To 
understand whether a common expression pattern of these two proteins exists in mouse brain, 
we decided to perform immunoblotting of mouse brain lysates at different developmental 
stages with antibodies against Cdkl5 and shootin1. Consistent with previous findings [89,83], 
Cdkl5 is lowly expressed at embryonic stage 18 (E18) and postnatal day 1 (P1), gets induced 
in the early post-natal days and gets stabilized at around P14, persisting through adulthood. 
Conversely, shootin1 is significantly expressed at E18, peaks in the first post-natal days and 
decreases to undetectable levels after P14 (Fig 1 B). 
The rather strong expression of both proteins in the early post-natal period allowed us to test 
whether Cdkl5 and shootin1 associate in vivo. Indeed, by co-immunoprecipitation assays with 
P7 brain lysates we were able to detect Shootin1 as co-precipitating with Cdkl5 but not with 
an unrelated anti-IgG. Moreover, in the reciprocal experiment, Cdkl5 co-precipitated with 
shootin1 (Fig 1 C). The immunoprecipitation assay thus confirmed the interaction identified 
in yeast and established that Cdkl5 and shootin1 form a complex in mouse brain. 
Since exogenously expressed shootin1 and CDKL5 in HEK293 cells did not co-
immunoprecipitate (data not shown), it is possible that the interaction requires other mediator 
proteins. 
 
 
Cdkl5 and shootin1 are co-localized in differentiating neurons and 
developing brain 
 
For further clarification, we analyzed whether the two proteins are physically present in 
neurons during the first stages of neuronal differentiation. We therefore cultured hippocampal 
neurons prepared from E16 mouse embryos and collected them at different time points (18, 
24, 48, 72, 96 hours and days in vitro 7 and 14 (DIV7 and DIV14)). By western blotting we 
found that both Cdkl5 and shootin1 levels are comparatively lower at 18 hrs hours after 
plating and get concomitantly induced between 40-72 hours and are significantly expressed 
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till 14 days (DIV14) of culturing (Fig 2 A). 
To assess the localization of Cdkl5 and shootin1 in cultured neurons, we performed 
immunofluorescence experiments with cultured E16 mouse hippocampal neurons at 18 and 
24 hrs after plating. Consistent with role of shootin1 in axonal specification we found it 
localized in the distal tip of minor neurites at both time points. Interestingly, Cdkl5, besides 
being present in the soma and the nucleus, was also found in the growth cone of neurites 
where it partially localizes with shootin1 (Fig 2 B). Altogether, the physical association of 
Cdkl5 and shootin1 and their co-localization in the growth cone of minor neurites is in line 
with a possible role of both proteins in regulating axon outgrowth. 
We further investigated the expression pattern of shootin1 and compared it with that of Cdkl5 
in the developing cortex through in situ hybridization and immunohistochemistry. 
The in situ hybridization assay demonstrated that both Cdkl5 and shootin1 mRNAs are 
present at detectable levels in E13 and E14 mouse embryonic cortical post-mitotic neurons, 
both in the proliferating zone (ventricular zone; VZ) and sub-ventricular zone (SVZ), and in 
neurons residing in cortical plate (CP). Apparently, at E16, shootin1 mRNA levels increase 
and significant levels of Cdkl5 and shootin1 mRNAs were detected in the cortex at E18, 
demonstrating the presence of shootin1 in the developing mouse brain together with Cdkl5 
(Fig 3).  
Immunohistochemistry experiments allowed visualizing shootin1 protein levels at different 
embryonic stages. In accordance with the in situ hybridization experiments, very low but 
detectable shootin1 signals were observed at E14 whereas significant levels were detected at 
E16 and E18. Moreover, we detected an overlapping signal of shootin1 and Tag1 (a 
glycoprotein expressed in the growing cortico-thalamic axonal connections) at E16. 
Gradually, at E18, the overlapping signals become prominent in fibres invading the internal 
capsule (IC) or the corpus callosum that is supposed to be cortico-thalamic or cortico-cortical 
connections, therefore, confirming the presence of shootin1 in cortical glutamatergic axons.  
 
 
Cdkl5 regulates shootin1 phosphorylation  
 
An early report suggested shootin1 to be a phosphoprotein but no data revealed the involved 
kinase or the functional consequences of this phosphorylation event [119]. However, recently, 
Toriyama and colleagues demonstrated that Pak1 (p21-activated kinase 1) phosphorylates 
shootin1 on at least two sites via activation of Cdc42 and Rac1 by netrin-1; interestingly, 
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these phosphorylation events seem to promote clutch engagement and formation of traction 
forces at the axonal growth cones, leading to axon outgrowth [117].  
Thus, considering the kinase activity of Cdkl5 and its interaction with shootin1 identified 
through the yeast two-hybrid screening and confirmed by immunoprecipitation, we speculated 
that Cdkl5 might work upstream shootin1 modulating its activity in developing neurons in a 
phosphorylation dependent manner.  
To analyze whether Cdkl5 is involved in phosphorylating shootin1, we first performed two-
dimensional (2D) SDS-polyacrylamide gel electrophoresis (SDS-PAGE) to detect the 
phosphorylation of shootin1 in cultured primary cortical neurons grown for 7 days in vitro. 
Seven distinct spots of shootin1 with different isoelectric points could be observed suggesting 
that shootin1 is indeed phosphorylated in cortical neurons. The intensity of the two most 
acidic spots was reduced when the extract was treated with lambda phosphatase (Fig 4 A) 
confirming that these two distinct spots correspond to phospho-isoforms of shootin1. The 
disappearance of the phospho-ERK signals in the lambda phosphatase treated extracts assures 
the efficient phosphatase activity.  
We further investigated the role of Cdkl5 in imposing the post-translational mark on shootin1. 
We therefore used primary cortical neurons silenced for Cdkl5 expression through infection 
with lentiviral particles expressing a shRNA against Cdkl5. As control, a shRNA against 
LacZ was used. By western blotting the efficient silencing of Cdkl5 7 days after plating and 
infection was confirmed (Fig 4 B). The infected neurons were distinguished by GFP that is 
concomitantly expressed by the virus. In this case, the three distinct GFP spots were used as 
an internal standard for aligning the spots corresponding to shootin1. Interestingly, we noticed 
a reduction in signal intensity of the two most acidic spots corresponding to the two phospho-
isoforms of shootin1. By normalizing the signal intensity of the distinct shootin1 isoforms to 
that of all the spots, we confirmed that the intensity of spots 6 and 7 was significantly reduced 
while spot 4 remained constant (Fig 4 C, D).  
Altogether, these experiments allowed us to propose that Cdkl5 works upstream shootin1, 
directly or indirectly affecting its phosphorylation. 
 
 
Cdkl5 and shootin1 levels influence neuronal polarization 
 
As described, it has been demonstrated previously that shootin1 regulates neuronal 
polarization through its accumulation in the distal tip of the axon to be. Since our results 
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indicate that Cdkl5 acts upstream shootin1, we found it challenging to analyze the role of 
Cdkl5 in axon formation.  
For this purpose, we prepared primary hippocampal neurons from E16 mouse embryos and 
infected the cells at the day of plating with lentiviral particles containing shRNA for silencing 
Cdkl5 and shootin1. Two shRNAs for each protein were used, designated as shCDKL5#1, 
shCDKL5#2, shShootin1#1 and shShootin1#2 and as negative control, shLacZ was used. 
These constructs and sites of annealing are schematically illustrated in figure 5 A and B. As 
shown in figure 5 C, the shRNAs against shootin1 were found to efficiently silence 
exogenously expressed shootin1 in HeLa cells.  
By western blotting we confirmed the efficient silencing of Cdkl5 and shootin1 in lysates of 
hippocampal neurons cultured for 96 hours after plating and infection (Fig 6 A). The infected 
neurons were easily distinguished through the concomitant expression of GFP. Morphological 
analysis of GFP-positive neurons demonstrated that a large amount of Cdkl5 deficient 
neurons displayed several long processes whereas others appeared stunted (Fig 6 B). On the 
other hand shootin1 deficient neurons appeared severely stunted devoid of any long process 
and bearing several small neurites. The immunostaining with the axonal specific marker Tau-
1 and the somatodendritic marker MAP2 was then performed to analyze how the loss of 
CDKL5 or shootin1 influenced axon specification. Tau-1 typically shows a proximal to distal 
increase in intensity while MAP2 segregates into the minor neurites shortly after axogenesis 
in developing cortical and hippocampal neurons. Three categories of neurons could thus be 
classified based on their Tau-1 and MAP2 staining. Neurons showing only one long axon and 
several small dendrites were considered as polarized whereas others contained multiple axons 
or no axon as illustrated in figure 7. Considering this, we observed that the vast majority of 
control neurons expressing shLacZ were showing one long axon and several neurites 
(polarized) (means ±SEM:90.32±0.63). Neurons devoid of Cdkl5 were significantly impaired 
in axon formation. Approximately 40% of the neurons silenced with shCDKL5#1 were not 
properly polarized; however, the situation was rather complex since 30% of the neurons bore 
multiple axons and the remaining 10% did not grow any axon. On the other hand, and as 
expected, a significant number of neurons silenced for shootin1 were devoid of axons (40%) 
whereas 56% appeared as polarized, and 3% had grown multiple axons (Fig 8 A). Similar 
data were obtained with shCDKL5#2 and shShootin1#2 demonstrating that they were not due 
to off target effects. Interestingly, neurons silenced with shCDKL5#2, which silences Cdkl5 
expression less efficiently, were less prone to generate multiple axons, suggesting that the 
level of the kinase is important to exhibit its effects on neuronal morphology. 
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Since Cdkl5 was previously found to regulate neurite outgrowth [83], we analyzed the length 
of axons and dendrites in neurons devoid of either Cdkl5 or shootin1 at 96 hours after plating. 
Shootin1 depleted neurons exhibited a marked reduction in the total length of axons and 
neurites in accordance with published data [114]. Conversely, neurons devoid of Cdkl5 did 
not show any significant alteration either in the total axon or neurite length (Fig 8 B). 
However, when the same analysis was performed exclusively with Cdkl5 depleted neurons 
that appeared as correctly polarized, we found a significant reduction in the total length of 
both axons and neurites in comparison with polarized control neurons (Fig 8 C). Notably, 
total dendrite length was not significantly changed in any of the samples. Presently, we cannot 
explain the discrepancy of our results and those of Chen [83]. However, since murine 
hippocampi and rat cortices have been used for the two studies, it may be difficult to directly 
compare the results. Moreover, the timing of the experiments is different: whereas Chen et al. 
analyzed neuronal morphology at DIV3 (from rat E18 embryos) our analyses were performed 
at DIV4 (from mouse E16 embryos), when a defect in neuronal polarization may be more 
prominent. 
In the above experiments we observed that shootin1 levels as detected by western blotting 
seemed reduced in neurons silenced for Cdkl5. As seen in figure 9 A, at both 72 and 96 hours 
after plating and lentiviral infection with the shRNAs against Cdkl5 shootin1 levels appeared 
significantly reduced. Further quantification of the expression level of shootin1 and Cdkl5, 
using the house keeping protein Tuj-1 for normalization, allowed us to conclude that shootin1 
levels are significantly decreased upon silencing of Cdkl5 (Fig 9 B). 
We next proceeded analyzing how increased CDKL5 or shootin1 levels influence neuronal 
polarization. To this purpose, we nucleofected hippocampal neurons, prepared from E17 
mouse embryos, a time point in which neurons were found to be more resistant to the 
treatment, with different vectors. Three expression vectors pCAGGS-shootin1-IRES-GFP, 
pCAGGS-Cdkl5-IRES-GFP and pCAGGS-Cdkl5-A40V-IRES-GFP, were used to 
overexpress shootin1, wild-type Cdkl5 and a disease causing Cdkl5 derivative (Cdkl5-A40V) 
that has significantly reduced catalytic activity (our unpublished data) in neurons (Fig 10). 
These vectors express GFP from an internal ribosome entry site (IRES). Neurons were 
nucleofected at DIV0 just before plating and were analyzed at DIV7 when significant 
overexpression of Cdkl5 and shootin1 could be determined by western blot analysis (Fig 11 
A). The majority of GFP positive control neurons (means ±SEM: 94.07±1.07) were correctly 
polarized and displayed only a single long Tau-1 positive axon and several dendrites. In 
contrast, Cdkl5 overexpressing neurons were significantly altered, bearing several Tau-1 
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positive long processes (means ±SEM:40.54±3.43%; n=129; Fig 11 B, C). In addition, 
neurons expressing the disease causing derivative, CDKL5-A40V, were characterized by the 
presence of multiple axons; however, the effect was not as strong as that caused by expression 
of wild-type CDKL5, suggesting that the catalytic activity plays a role in regulating axon 
formation (means ± SEM:27.6±7.5% n=123; Fig 11 C). Consistent with the previous results 
observed by Toriyama and colleagues, neurons overexpressing shootin1 displayed multiple 
axons as well (means ±SEM:48.71±2.54%; n=123). These experiments thus demonstrate that 
excess of either shootin1 or CDKL5 disturb neuronal polarization in a similar way. 
Altogether, our data suggest that neuronal polarization and axon specification require proper 
levels of both CDKL5 and shootin1. 
 
 
Shootin1 regulates neuronal migration in vivo 
 
The neo-cortex controls nearly all aspects of brain activities, including perception, language, 
and decision-making. It contains an immense number of neurons produced through extensive 
progenitor cell divisions in the lateral ventricle of the cerebral cortex. These neurons are 
spatially organized into six horizontal layers, called cortical layers, where newly born neurons 
migrate in an inside out manner through the sub-ventricular zone, the intermediate zone and 
form the outer cortical layer while later born neurons reside elsewhere in the cortex forming 
different cortical layers. The formation of this laminar structure requires the exquisite control 
of neuronal migration from their birthplace to their final destination.  
Studies suggested that CDKL5 effects neuronal migration in rat and mouse brains [83,97], 
whereas the role of shootin1 for neuronal migration was unknown. To explore the role of 
shootin1 in neuronal migration, we performed in utero electroporation (IUE) experiments. 
This technique is an alternative tool to genetically engineer animals and the overexpression 
and/or knockdown of target genes can easily be achieved by introducing expression vectors 
into the proliferating zone (ventricular zone; VZ) of the mouse cerebral cortex at certain 
embryonic stages. The concomitant expression of GFP/RFP allows tracking the genetically 
modified neurons for migration defects at later stages of development as illustrated in figure 
12. 
GFP-expressing shShootin1#1 and #2 or shLacZ expressing pLentiLox3.7 vectors were thus 
injected into the lateral ventricle of E13 embryonic mouse brains and subsequently 
electroporated into the neuronal progenitors of the ventricular zone. After allowing embryos 
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to grow in vivo for four days (E17), the GFP signal was used to follow migration of 
transfected neurons (Fig 13 A, B). The distribution of GFP positive cells in the neocortex was 
calculated by its subdivision into five distinct areas (Fig 14 A): outer cortical layer (OCL), 
middle cortical layer (MCL), inner cortical layer (ICL), intermediate zone/sub-ventricular 
zone (IZ/SVZ), and ventricular zone (VZ). GFP positive cells were counted in each area and 
normalized against the total number of GFP positive cells from all areas. In control embryos 
expressing shLacZ, we observed almost 50% of GFP positive cells in the outer cortical layer. 
Conversely, the majority of shShootin1#1 expressing GFP positive cells (roughly 40%) 
resided in the intermediate zone/sub-ventricular zone (IZ/SVZ) and less than 20% reached the 
outer cortical layer (OCL) (Fig 14 B). Shootin1 thus appears to be required for correct 
neuronal migration in the developing neocortex in accordance with recently published results 
[117]. Similar results were obtained with shShootin1#2 (data not shown) indicating the 
specificity of the phenotype. The shCDKL5-transfected embryos displayed a migration defect 
similar to that of previous reports [83,97] (Fig 15 A, B). 
To analyze whether the migration defect caused by the absence of shootin1 persists at later 
time points of brain development we allowed E13 electroporated embryos to develop till P0 
or P8. Our analysis at P0 showed that a significant number of neurons (roughly 25%) was in 
IZ/SVZ (Fig 16 A, B and 17). Furthermore, at P8 the majority of neurons were still in the 
intermediate zone/sub-ventricular zone (IZ/SVZ) (statistic analysis was not done at this stage 
due to lack of controls embryos) compared to control embryos expressing LacZ (Fig 16 C, 
D); altogether this suggests that the loss of shootin1 may cause long-term effects in neuronal 
migration during brain development.  
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FIGURE 1. Shootin1 associates with CDKL5 in vivo. A. A yeast-two hybrid screening 
identified shootin1 as a CDKL5 interacting protein. The upper diagram depicts hCDKL5 and, 
in blue, the region spanning amino acids 299-1030 that was used as bait. The diagram below 
indicates shootin1 with its coiled coil domains in black. The black bars below show the 
human clones identified in the screening. The red bar represents the minimum CDKL5 
interacting region. B. Immunoblot analysis showing Cdkl5 and shootin1 levels in whole cell 
lysates from mouse brains at various developmental stages. Tuj-1 was used as loading control. 
C. Co-immunoprecipitation experiments where P7 brain lysates were immunoprecipated with 
anti-CDKL5 (left) or anti-shootin1 (right) antibodies. IgG’s were used as negative control. 
Inputs correspond to 5% of the total cell lysates of mouse brain. Asterisks (*) indicate the 
immunoglobulin heavy chains in the immunocomplexes.  
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FIGURE 2. Shootin1 localizes with Cdkl5 in growth cones. A. Western blot analysis 
showing Cdkl5 and shootin1 levels in cultured murine hippocampal neurons at the indicated 
stages. Tuj-1 was used as loading control. A longer exposure of the 18 h time point is shown 
to the right. B. Immunofluorescence experiment showing Cdkl5 and shootin1 localization in 
hippocampal neurons cultured for 18 and 36 hours in vitro. Neurons were double stained with 
anti-shootin1 (green) and anti-CDKL5 (red). The small inserts show a magnification of the 
growth cones.  
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FIGURE 3. Expression pattern of Shootin1 and Cdkl5 in the developing mouse brain. 
Shootin1 is expressed in the cortex, as early as E13, in the cortical plate (CP) and its levels 
increase ongoing with development (A, B, E); Cdkl5 (C, F) and Tag1 (D) follow the same 
pattern. Low but detectable levels of shootin1 and Cdkl5 mRNAs are present in cells 
migrating out of the ventricular and sub-ventricular zone (VZ-SVZ) towards their final 
destination in the cortical plate (B, C). At E14, shootin1 protein can be detected in the CP (G, 
G’). Starting from E16, shootin1 protein levels are detected not only in cell bodies, but also in 
fibers both in the cortex in the intermediate zone (IZ) and in the internal capsule (IC); in both 
the cases shootin1 (red) and TAG1 (green) staining overlap (H, H’, H’’, K, K’, K’’). At E18 
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shootin1 and Cdkl5 are strongly expressed throughout the whole thickness of the cortex (I, J). 
Scale bars: 50 mm: B, C, D, E, F, G, G’; 100 mm: H, H’, H’’, I, J, K’, K’’; 500 mm. 
 
 
 
 
 
FIGURE 4. Cdkl5 mediates shootin1 phosphorylation in primary cortical neurons. A. 
Total cell extracts of DIV7 cortical neurons were treated with or without lambda protein 
phosphatase and analyzed by two-dimensional gel electrophoresis and immunoblotting with 
antibodies against shootin1, beta-actin and, as control for the phosphatase treatment, phospho-
ERK1/2. B. Primary murine cortical neurons were infected with shLacZ or shCdkl5 
expressing viral particles at DIV0 and Cdkl5 silencing verified by western blotting on total 
cell lysates using Tuj1 as loading control. C. Total cell lysates from DIV7 cortical neurons in 
(B) were subjected to two-dimensional gel electrophoresis. Shootin1 and GFP were detected 
by immunoblotting. The three GFP isoforms were used as internal standard for alignment. D. 
Graphic illustration showing the results of densitometric scanning quantification of spots 1-7 
of shootin1 in shLacZ or shCdkl5 expressing neurons ±SE (**p<0.01; n=2). The intensity of 
the single spots was normalized to that of all seven spots. 
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Figure 5. Graphic illustration of short hairpin RNAs expression vectors, their sites of 
annealing and western blot; A. 1. pLentiLox3.7-shLacZ, 2. pLentiLox3.7-shCDKL5#1, #2, 
3. pLentiLox3.7-shshootin1#1, #2, #3. Short hairpins against Cdkl5 and shootin1 were 
inserted into HpaI-XhoI sites of pLentiLox3.7 where Hpa1* denotes the loss of its restriction 
site after cloning. GFP expression is under control of CMV regulatory sequences. B. 1. 
shCDKL5#1 and #2 anneal at nucleotides 68-87 and 1856-1876 of the Cdkl5 ORF, 
respectively. 2. shShootin1#1 and #3 anneal at nucleotides 705-724 and 1200-1221 of 
shootin1 ORF, respectively, while shShootin#2 anneals at 3481-3501 of the 3’UTR. C. 
Western blot analysis showing the shRNA mediated silencing of exogenously expressed 
shootin1 in Hela cells. The cells were transfected with: 1. pCAG-IRES-GFP; 2. pCAG-
Shootin1-IRES-GFP; 3. pCAG-Shootin1-IRES-GFP+pLentiLox3.7-ShShootin1#3; 4. pCAG-
Shootin1-IRES-GFP+ pLentiLox3.7-ShShootin1#2; 5. pCAG-Shootin1-IRES-
GFP+pLentiLox3.7- ShShootin1#1. Tubulin was used as a loading control. shShootin#1 and 
shShootin1#2 were used for further experiments due to their higher silencing efficiency. 
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FIGURE 6. Cdkl5 and shootin1 knock-down cause aberrant neuronal polarization. A. 
Western blot showing Cdkl5 and shootin1 levels in primary hippocampal neurons infected 
with shRNAs against Cdkl5, shootin1, or, as control, LacZ. Neurons were infected at DIV0 
and cell lysates prepared after 96 hours. Tuj1 was used as loading control. B. Representative 
images of neurons 96 hours after plating and infection with viral particles expressing GFP 
together with shRNAs against LacZ, Cdkl5, or shootin1. The image corresponds to the GFP 
signals. Scale bar, 25 μm. Arrows indicate stunted neurons devoid of Cdkl5. 
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Figure 7. Representative images showing typical Tau1 and MAP2 staining of polarized 
neurons and those with multiple or no axons. Correctly polarized neurons bear only one 
long Tau-1 positive axon and several MAP2 positive dendrites. Non polarized neurons can be 
classified as having multiple axons or no axons. Tau1 staining is in blue, MAP2 in red and 
GFP in green. The merge shows the overlap of the three different stainings. Scale bar, 25μm. 
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FIGURE 8. Analysis of polarization defects in neurons devoid of Cdkl5 or shootin1. A. 
Graph showing the polarization of neurons expressing shRNAs against LacZ, Cdkl5 or 
Shootin1. Polarized neurons (with one axon) are indicated with black bars, those with 
numerous axons with dark grey bars and neurons with no axon with light grey bars. Data are 
expressed as ±SE (***p<0.001; n=3, a total of 725 neurons were examined). B. 
Quantification of neurite length of the entire population of GFP-positive neurons at DIV4. 
The length of axons and dendrites were measured in neurons expressing shRNAs against 
LacZ, Cdkl5, or shootin1 (a total of 117 neurons were analyzed). C. Quantification of neurite 
length of GFP-positive neurons bearing one axon (a total of 74 neurons were analyzed). Data 
in B and C present neurite length as means ±SE, ***p<0.001. 
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FIGURE 9. Shootin1 levels are reduced in neurons devoid of Cdkl5. A. Western blot 
analysis showing reduced shootin1 protein levels at the indicated time points in Cdkl5 
silenced neurons. Tuj1 was used as loading control. 1; shCDKL5#1, 2; shCDKL5#2, 3; 
shLacZ. B. Graphic representation showing Cdkl5 and shootin1 protein levels in neurons 
expressing shCDKL5#1 or shLacZ. Cdkl5 and shootin1 levels were normalized with Tuj1. 
**p<0.01, *p<0.05, n=3. 
 
 
 
FIGURE 10. Graphic illustration of expression vectors. 1. pCAGGS-mCdkl5-IRES-GFP; 
2. pCAGGS-mCdkl5A40V-IRES-GFP; 3. pCAGGS-Shootin1-IRES-GFP. The Cdkl5, 
Cdkl5A40V and shootin1 cDNAs were cloned into pCAGGS-IRES-GFP.  
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FIGURE 11.  Increased Cdkl5 levels affect axon specification in primary hippocampal 
neurons. A. Western blot analysis of primary hippocampal neurons nucleofected before 
plating with vectors expressing GFP alone or together with Cdkl5 or shootin1. Cell lysates 
were prepared at DIV7 and analyzed for Cdkl5 and shootin1 expression using Tuj1 as loading 
control. B. Representative images of hippocampal neurons expressing GFP together with 
exogenous Cdkl5 or shootin1. Nucleofected hippocampal neurons were analyzed at DIV7 by 
staining with anti-Tau1 (red) and anti-GFP (green) antibodies. Scale bar, 25 μm. C. 
Quantitative analysis of neuronal polarity in overexpressing neurons. Axon specification was 
analyzed by determining the number of polarized neurons with a single axon (black bars), 
neurons with multiple axons (dark grey bars), and neurons with no axon (light grey bars). 
Data are expressed as mean of four independent experiments ± SE; ***p<0.001; a total of 461 
neurons were analyzed. 
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FIGURE 12. Illustration of in utero electroporation of injected DNA. A. Injection of a 
DNA containing solution through a fine capillary needle into the lateral ventricle of exposed 
embryos is followed by gene delivery into the ventricular zone (VZ) via electroporation by 
holding the embryos with forceps-type electrodes. B. The neuroepithelium is targeted by 
placing the positive electrode on the dorsal lateral side. GFP expressing electroporated cells 
are indicated in green. LV, lateral ventricle; NC, neocortex. Adapted from Taniguchi et al., 
2012 [120]. 
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FIGURE 13. Loss of shootin1 causes neuronal migration defects. Representative images 
of coronal slices of E17 mouse brains expressing GFP together with shRNAs against either 
LacZ (A) or shootin1 (B) through in utero electroporation at E13. Staining with anti-GFP and 
DAPI was used to visualize transfected neurons and nuclei, respectively. CP, cortical plate; 
IZ, intermediate zone; SVZ, subventricular zone; VZ, ventricular zone. Scale bar, 25μm. 
 
 
 
FIGURE 14. Neuronal migration deficits in the absence of shootin1. A. The dorsal 
telencephalon was divided into the five layers used for the quantification of migrating cells. 
B. Quantification showing the percentage of transfected neurons in the distinct layers, i.e. 
OCL, outer cortical layer; MCL, middle cortical layer; ICL, inner cortical layer; IZ, SVZ, and 
VZ. *p<0.05, **p<0.01, ***p<0.001. 
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FIGURE 15. Cdkl5 regulates neuronal migration during brain development.  
Immunohistochemistry of E18 mouse embryonic coronal slices, electroporated with ShLacZ 
(A) or ShCDKL5#1 (B) at E14. GFP expressed from the lentiviral vectors, was used to trace 
migrating transfected neurons. DAPI was used to visualize transfected/non-transfected 
neurons nuclei. Scale bar, 25μm. 
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FIGURE 16. Long term-effect of shootin1 in neuronal migration of the developing 
cortex.  Immunohistochemistry of P0 (A, B) and P8 (C, D) coronal mouse brain slices, 
electroporated at E13 with vectors expressing shRNAs against Shootin1 or LacZ. Scale bar, 
25μm. 
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Figure 17. Graphic representation of neuronal migration deficits in the cerebral cortex 
at P0 under the influence of shootin1 depletion. Analysis showing percentage of neurons 
transfected at E13 in the distinct layers of the cerebral cortex at P0. *p<0.05, n=3. 
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Rett syndrome (RTT) is a post-natal neurodevelopmental disorder characterized by a period 
of normal development followed by the loss of intellectual functioning, fine and gross motor 
skills and communicative abilities, deceleration of head growth leading to microcephaly, and 
the development of stereotypic hand movements [2]. Girls with RTT often develop seizures 
ranging from easily controlled to intractable epilepsy, which decrease in severity after the 
teenage years and present less severe problems in adulthood [62]. RTT, which is considered 
to be one of the most common causes of complex disability in girls, is caused by mutations in 
the methyl-CpG-binding protein 2 gene (MECP2) in at least 95% of individuals fulfilling the 
criteria for classic RTT. Besides classical RTT, other atypical forms of the disease have been 
recognized in a small proportion of clinically well-defined Rett syndrome cases but with an 
apparent lack of MECP2 mutations. In particular, three distinct variant forms of RTT, 
including the preserved speech variant [56], the congenital variant [57] and the early-onset 
seizure variant (ESV; [58]) have been well described. Mutations in the X-linked cyclin-
dependent kinase-like 5 gene (CDKL5) have been identified in patients with the ESV of Rett 
syndrome and other neurological disorders that share the common features such as the 
appearance of often intractable seizures during the first months of life, infantile spasms, 
hypotonia, and severe intellectual disability [78]. The Neul criteria [5] for atypical RTT 
describe five specific items to differentiate the ESV from other variants. Although mutations 
in the CDKL5 gene have been associated with the early-onset variant of RTT, the CDKL5 
disorder has recently started being considered a separate disorder rather than another RTT 
variant [78]. The reason for this is principally the lack of a regression period, which is a strict 
requirement for the RTT diagnosis and, moreover, that various dysmorphic features including 
large deep-set eyes, strabismus, high forehead, full lips, wide mouth and widely spaced teeth, 
have been described in individuals with CDKL5 mutations. However, the partial clinical 
overlap observed in patients with CDKL5 and MECP2 mutations, such as the presence of 
stereotypic hand movements, typical for Rett syndrome, suggest that some common 
molecular pathways are disrupted in these two groups of patients. A possible explanation 
might be that CDKL5 is involved in phosphorylating MeCP2 even if in vivo evidence still 
needs to be found [45]. 
The involvement of CDKL5 in the etiology of the Hanefeld variant and related disorders urges 
a detailed characterization of the role of this protein in neuronal activities. Although rather 
little is still known about the functions of CDKL5, the neurological dysfunctions underlying 
the etiology of CDKL5 associated disorders have recently started being elucidated [82]. The 
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development of the central nervous system (CNS) starts early in embryogenesis where distinct 
pattern of gene expression governs various neuronal subtypes. A range of molecular 
signalling cascades guide these neurons to maintain their morphology to form complete 
neuronal circuits and disruption of such regulatory pathways increases the susceptibility to 
various psychiatric and neurodevelopmental disorders. The striking organization of the 
neocortex into distinct layers contributes to increasing functional complexity of the 
mammalian brain and deficits in cortical development, resulting from defects in cell 
proliferation in the germinal zone, aberrant neuronal migration or connectivity and 
differentiation frequently cause epilepsy. Moreover, the cytoskeleton drives the process of 
neuronal polarization and morphology, important for the transmission of signals from one 
neuron to another. Given that the hippocampus and cerebral cortex are considered to be the 
most epileptogenic regions of the brain [121] it is interesting to note that these are the two 
brain areas expressing highest amounts of CDKL5 [89]. Moreover, the expression profile of 
CDKL5 suggests that it plays a role during the early steps of post-natal differentiation and this 
might, at least in part, fit with the precocious symptoms of CDKL5 related pathologies. 
Accordingly, it is intriguing to speculate that seizures, representing one of the characteristic 
phenotypes of patients with mutations in CDKL5, might originate from these deficits. 
A delay in the migration of neuronal precursors devoid of CDKL5 through the developing 
cortex has already been reported [83, 97], reinforcing the idea that defective CDKL5 activity 
might affect early steps of differentiation by altering molecular processes that not only impact 
cytoskeletal modifications but eventually result in a delayed refinement of cortical 
architecture. Moreover, recent observations on the role of CDKL5 proved that it regulates 
neuronal morphology [83,97]. However, the recently developed Cdkl5 knock-out mouse 
model does not display any gross alterations in brain structure, even though a detailed 
analysis of neuronal morphology has not yet been reported [106]. 
In neurons, CDKL5 is present both in the cytosolic and nuclear compartments [89] where it 
interacts with specific proteins to maintain neuronal morphology and functions. Considering 
the fact that CDKL5 interacts with DNMT1 [98], MeCP2 [45], the SR family splicing factor 
(SC35) [45] in the nucleus and with Rac1 [83], PSD95 [100] and NGL-1 [97] outside the 
nucleus, especially at synapses, it seems likely that the protein plays important roles ranging 
from regulating gene expression to the formation of spines. Given that the molecular 
mechanisms by which CDKL5 exerts such functions are far from being understood, we aimed 
at identifying novel CDKL5 interactors that might help shedding light on its role in neuronal 
functions. In a yeast two hybrid screening we identified shootin1 as a novel interactor of 
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CDKL5. As described, shootin1 is a brain specific intracellular protein acting as a 
determinant of axon formation during the process of neuronal polarization [114]. The 
expression of shootin1 gets upregulated during the period of axon formation and elongation, 
and, in particular, its asymmetric accumulation in the tip of the neurite that will become an 
axon is required for proper axon specification. Indeed, genetic manipulations disturbing this 
asymmetric distribution of shootin1 impairs neuronal polarization.  
The interaction between CDKL5 and shootin1 thus led us to hypothesize a role of CDKL5 in 
this particular process of neuronal differentiation. By analyzing in details the functional 
interplay between shootin1 and CDKL5 we found evidence that CDKL5 is involved in 
regulating neuronal polarization, possibly through its interaction with shootin1. First of all, 
we observed low levels of CDKL5 in unpolarized hippocampal neurons and a strong 
induction in the transition from stage 2 to stage 3 where it localizes together with shootin1 in 
the distal tip of neurites or outgrowing axons. Moreover, we find that the two proteins 
associate in vivo in early post-natal brains and that correct CDKL5 levels are required for 
proper axon formation. Indeed, the majority of hippocampal neurons over-expressing CDKL5 
generate a surplus of axons whereas a significant number of neurons devoid of it were not 
correctly polarized. A disease causing mutation of CDKL5, CDKL5-A40V, which has 
reduced catalytic activity (our unpublished data), was less efficient in generating the multiple 
axon phenotype, indicating that the kinase activity is required for CDKL5 to influence axon 
formation. Altogether, these observations indicate that correct neuronal polarization requires 
balanced levels of functional CDKL5.  
Proper levels of shootin1 are a prerequisite for neuronal polarization [114] and, as described, 
it has been suggested to act as a linker that couples actin filament flow to the substrate, 
allowing the formation of the traction forces at axonal growth cones [117]. Shootin1 has 
previously been described as a phosphoprotein; in fact, shootin1 phosphorylation, which is 
induced by the activation of both Pak1 and cdc42/Rac1, is required for its association with the 
actin retrograde flow. Interestingly, we found that shootin1 phosphorylation is reduced in 
neurons silenced for CDKL5 reinforcing the idea that the two proteins work in a common 
molecular pathway. Whether CDKL5 directly or indirectly phosphorylates shootin1 remains 
to be revealed as well as the specific residues of shootin1 whose modification depends on 
CDKL5. In vitro phosphorylation experiments in which recombinant shootin1 was incubated 
with immunopurified CDKL5 did not reveal any significant phosphorylation of shootin1 (data 
not shown). Moreover, given the lack of available consensus sites for CDKL5, the mapping of 
its putative targets within shootin1 proves difficult. Serines 101 and 249 within shootin1 were 
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found as Pak1 targets and their phosphorylation is required for shootin1 to interact with the F-
actin retrograde flow [117]. Future experiments will reveal whether the phosphorylation of 
these two serine residues depends on CDKL5. In addition, it is interesting to note that Rac1 
appears to be common to the pathways of both CDKL5 and shootin1. As mentioned, shootin1 
phosphorylation is induced by cdc42/Rac1 dependent Pak1 activation and CDKL5 has been 
reported to regulate neuronal morphology acting upstream Rac1 [83,117]. It will be therefore 
be interesting in the future to analyze whether CDKL5 exerts its regulatory functions on 
shootin1 in a Rac1 dependent manner. 
Intriguingly, the expression level of shootin1 was significantly reduced in hippocampal 
neuronal cultures silenced for CDKL5. Whether this is caused by a transcriptional or post-
transcriptional effect still remains unclear. It is interesting to note that the selective action of 
the ubiquitin-proteasome system (UPS) has been suggested to be involved in axon/dendrite 
differentiation [122,123]. The phosphorylation of some proteins has been found to render 
them less susceptible for E3 ligase dependent degradation. For example, Akt, a key regulatory 
protein in the PI3-kinase/Akt signaling pathways, is present in phosphorylated and 
unphosphorylated forms in axon and dendrites respectively. The dendritic unphosphorylated 
Akt is more susceptible to UPS-dependent degradation than axonal phospho-Akt and the 
selective degradation of unphosphorylated Akt thus represents a means to maintain the 
asymmetric distribution of Akt/phospho-Akt in polarized neurons [123]. Likewise, 
phosphorylation of LKB1 enhances its stability by the formation of LKB1/STRAD complex 
thereby reducing its susceptibility of ubiquitinylation. In an analogous situation, it could be 
speculated that phosphorylation of shootin1 might regulate its stability. By treating neurons 
silenced or not for Cdkl5 with the proteasome inhibitor Mg132 we addressed this point but 
did not yet obtain conclusive results. Alternatively, the activity or substrate specificity of 
specific E3 ligases may be regulated by their post-translational modification [124]. In the 
yeast two-hybrid screening, UBE4A (U-box-type ubiquitin ligase) and KLHL7 (a protein of 
the BTB-Kelch family that is implicated in ubiquitinylation through Cullin E3 ligases; [125]) 
that are both involved in ubiquitin mediated protein degradation were found as CDKL5 
interactors. Therefore, it could also be speculated that CDKL5 controls the activity of factors 
involved in regulating shootin1 turnover.  
Even if the main body of our experiments is in line with a role of CDKL5 in neuronal 
polarization through its association with shootin1, the picture is complicated by the fact that 
silencing of CDKL5 generates a mixed phenotype including both neurons devoid of axons 
and neurons with numerous axons. On the other hand, CDKL5 is very likely to activate 
	   79	  
different downstream pathways through its diverse interaction partners and may thus target 
different factors involved in regulating axon specification and outgrowth. A kinome profiling 
of brain extracts from Cdkl5-null mice revealed that several signalling pathways are 
deregulated in its absence. Interestingly, the three pathways that were mostly influenced were 
those including AMPK kinase, PKA, and Akt that are all involved in neuronal polarization 
[106]. Moreover, as mentioned, CDKL5 works upstream of Rac1 [83] and it is well 
established that Rac1 influences various aspects of neuronal morphogenesis through different 
upstream regulators and downstream effectors. Axon initiation is mediated by Rac1 in a 
pathway involving DOCK7 and stathmin whereas this small Rho GTPase appears to have a 
dual role in regulating axon outgrowth: its inhibitory activity requires a pathway including 
PAK, LIMK, and cofilin whereas growth promotion is PAK independent [126]. It is possible 
that the silencing of CDKL5 has different efficiency and/or timing in different neurons thus 
influencing its down-stream effectors in distinct time windows with opposing outcomes.  
As previously stated, along with shootin1, several other proteins were found to interact with 
CDKL5 in the yeast two-hybrid screening. These proteins attained lower biological scores 
than shootin1 but the importance of these CDKL5 interactors in CNS development cannot be 
ruled out. Among the interactors were: (1) Formin-like 2 (FMNL2), which is predominantly 
expressed in brain and known as a putative regulator of Rho-GTPases. It serves as a novel 
elongation factor of actin filaments and promotes actin polymerization at the tips of 
lamellipodia [127]. Interestingly, micro-deletions including FMNL2 have been found 
associated with mental retardation [128]; (2) Glucocorticoid receptor DNA binding factor 1 
(GRLF1), also termed as p190A (a member of RhoGAP protein family) is prominently 
expressed in the developing and adult brain. Protein kinase C stimulation or integrin 
activation leads to outgrowth processing and neuronal development by rapid translocation of 
p190A to lamellipodial regions [129,130]. Mice devoid of p190A show several defects in 
neuronal development indicating the role of this protein in axonal outgrowth and/or guidance 
[131]; (3) Dystonin (DST) is one of the larger members of spectrin superfamily of 
cytoskeletal interacting proteins. Neuronal dystonin isoforms interact with actin and 
microtubule networks, protein complexes, membrane bound organelles and cellular 
membranes. Mutations in DST cause an aggregation of axonal neurofilament and 
disorganization of axonal microtubule in sensory neurons in a neurodegenerative disorder, 
dystonia musculorum [132,133]; (4) Heavy chain of kinesin-1 (KIF5A), a neuronal 
microtubule motor protein, which plays an important role in outgrowth processing and axonal 
transport of mitochondria. The absence of KIF5A affects motor neurons more severely than 
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sensory neurons [134]. Mutations in this gene cause autosomal dominant hereditary spastic 
paraplegia 10 (SPG10), a group of genetically heterogeneous neurodegenerative disorders 
characterized by distal axonopathy that affects the longest axons in the cortico-spinal tract 
[135]; (5) Adenomatous polyposis coli (APC), a tumor suppressor gene, which is highly 
expressed in developing brain [136] and is mainly associated with the plus ends of 
microtubule that maintains the cell polarity [137]. Interestingly, APC is localized at growth 
cones of hippocampal axons and disruption of this protein interferes with axon specification 
[138,139]. 
Since neuronal morphology is established in a manner depending on an interplay of balanced 
positive and negative signals regulating different signaling cascades that range from 
maintaining cytoskeleton structures to correct localization of polarizing molecules, it is worth 
speculating that altered CDKL5 levels might cause a deregulation of one or more of the above 
mentioned proteins and thus interfere with neuronal polarization at different levels. 
 
Normal cognitive function relies on the proper coordination of multiple steps of neuronal 
development and the correct neuronal migration throughout gestation and post-natal stages. 
During development, newly born post-mitotic neurons in the ventricular zone (VZ, mainly 
glutamatergic pyramidal neurons) migrate radially in an “inside out” fashion to their final 
positions in the developing cortex whereas GABAergic interneurons migrate tangentially 
from medial ganglionic eminence (MGE) to the cortex and reside there. Several studies have 
suggested that mutations in cytoskeletal regulators, extracellular matrix molecules, or post-
translational modifiers tend to affect both radial and tangential migration [140]. Disruption in 
the early steps of neuronal development, including neuronal migration, can result in severe 
cognitive deficits and epilepsy. For example, mutations in the human doublecortin gene 
(DCX) cause defects in cortical neuronal migration and patients with DCX mutations have 
lissencephaly and infantile spasms [141]. In addition, defects in axonal growth are likely 
associated with abnormal connectivity and may be associated with seizure pathogenesis as 
seen in lissencephaly. Thus, the causative genes have a role in both stages of development, 
closely relating the molecular pathways regulating neuronal migration and axon outgrowth. 
The observed impairments in neuronal migration in neocortices depleted for shootin1 
resemble the situation regarding CDKL5 [83] and suggest the importance of shootin1 in the 
developing nervous system. Though our IUE experiments show that the majority of silenced 
neurons still reside in the intermediate zone at post-natal stage P8, we are not yet in a position 
to say whether this effect is persistent throughout the development or it is just a delay in 
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migration as have been described for CDKL5. Further experiments in which migration of 
silenced neurons is analyzed at later post-natal stages are required to determine the long-term 
effect of shootin1 in neuronal development as well as in neuronal migration. Although so far 
no studies have described mutations in the SHOOTIN1 gene in humans, our findings suggest 
the possibility of its involvement in neurodevelopmental disorders and further studies are 
strongly recommended to validate the involvement of SHOOTIN1 in neurological disorders. 
Altogether, our data indicate a hitherto uncharacterized role of CDKL5 in the early phases of 
neuronal differentiation that may explain in part the clinical features associated with 
mutations in this gene. Finally, both the association of shootin1 with a molecular pathway 
belonging to CDKL5 and the defects in neuronal migration caused by its deficiency might 
make this gene an interesting candidate gene to analyze in patients with neurological 
disorders.  
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